CURRICULUM VITAE PERSONAL DATA Name: David Allen Boothman Present Address: 6834 Mimosa Lane Dallas, Texas 75230 Current Contact Information: Tel.: (214)648-9255 (330) 212-2158 (cell) e-mail: [email protected]EDUCATION High School: Notre Dame High School, Harper Woods, MI. Sept., 1972-May, 1976. Undergraduate: B.S., University of Michigan Sept., 1976- May, 1981. Graduate: Ph.D., Department of Microbiology & Immunology, (Thesis Advisor: Sheldon B. Greer, Ph.D.), University of Miami, Sept. 1981- Jan. 1986. POSTDOCTORAL TRAINING Postdoctoral Fellow: Department of Biological Chemistry and Molecular Pharmacology and the Division of Cell Growth & Regulation, Dana-Farber Cancer Institute, Harvard Medical School, (Mentor: Arthur B. Pardee, Ph.D.) Boston, MA. Sept. 1986- Nov. 31, 1989. PROFESSIONAL POSITIONS Assistant Professor, The University of Michigan, Department of Radiation Oncology, Division of Cancer Biology, 1331 East Confidential Page 1 6/6/2022 1
Transcript
CURRICULUM VITAE
PERSONAL DATA
Name: David Allen BoothmanPresent Address: 6834 Mimosa Lane
High School: Notre Dame High School, Harper Woods, MI. Sept., 1972-May, 1976.
Undergraduate: B.S., University of Michigan Sept., 1976- May, 1981.
Graduate: Ph.D., Department of Microbiology & Immunology, (Thesis Advisor: Sheldon B. Greer, Ph.D.), University of Miami, Sept. 1981- Jan. 1986.
POSTDOCTORAL TRAINING
Postdoctoral Fellow: Department of Biological Chemistry and Molecular Pharmacology and the Division of Cell Growth & Regulation, Dana-Farber Cancer Institute, Harvard Medical School, (Mentor: Arthur B. Pardee, Ph.D.) Boston, MA.Sept. 1986- Nov. 31, 1989.
PROFESSIONAL POSITIONS
Assistant Professor, The University of Michigan, Department of Radiation Oncology, Division of Cancer Biology, 1331 East Ann Street, Rm# 4131, Ann Arbor, Michigan, 48109. December 1, 1989-June 30, 1993.
Assistant Professor, The University of Wisconsin-Madison, Department of Human Oncology, K4/626 University of Wisconsin-Madison Medical Center, 600 Highland Avenue, Madison, Wisconsin 53792. July 1, 1993- Feb. 1, 1996.
Associate Professor, The University of Wisconsin-Madison, Department of (w/Tenure) Human Oncology, K4/626 University of Wisconsin-
Madison
Confidential Page 1 4/8/2023
1
School of Medicine, 600 Highland Avenue, Madison, Wisconsin 53792.
Feb. 2, 1996- August 31, 1998.
Other Associations at UW: Trainer, Program in Environmental Toxicology, University of
Wisconsin-Madison, 550 Babcock Drive, Madison, WI 53706-1293.
July 1, 1993 - August 31, 1998.Trainer, Human Cancer Biology, University of Wisconsin-
Madison, 600 Highland Avenue K4 CSC, Madison, WI.
July 1, 1993 - August 31, 1998.Trainer, Developmental Biology, University of Wisconsin-
Madison, 6459 Medical Sciences Building, Madison, WI,
October 1993 - August 31, 1998.Trainer, Program in Cellular and Molecular Biology,
University of Wisconsin-Madison, 413 R.M. Bock Laboratories, 1525 Linden Drive, Madison, WI.
December 1993 - August 31, 1998.Trainer, M.D./Ph.D. Integrated Degree Program, University
of Wisconsin-Madison, 1300 University Avenue, Madison, WI.
December 1993 - August 31, 1998.Trainer, Molecular and Cellular Pharmacology Program,
University of Wisconsin-Madison, 3795 Medical Sciences Center, 1300 University Avenue, Madison, WI 53706-1532.
December 1996 - August 31, 1998.Trainer, Biology of Aging and Age-related Diseases,
University of Wisconsin-Madison, Institute on Aging, VA Hospital, GRECC, 2500 Overlook Terrace, Madison WI 53705.
September 1996 - August 31, 1998.Vice Chairman, Department of Human Oncology Basic Research Division,
Representative for Basic Science Chairman Caucus and Senate Representative,
September 1, 1997- August 31, 1998.
Associate Professor, Case Western Reserve University School of (w/Tenure) Medicine, Department of Radiation Oncology,
Full Professor, Case Western Reserve University School of Medicine, (w/Tenure) Department of Radiation Oncology,
Laboratory of Molecular Stress Responses, and Case Comprehensive Cancer Center. Wolstein Research Building WRB 3-531, 2103 Cornell Rd., Cleveland, OH, 44106-4942
July 1, 2001 - June 30, 2005. Associate Director, For Basic Research, CWRU-UH-CCF Case
Comprehensive Cancer Center, Cleveland, OHNovember, 2002-June 30. 2005.
Co-Director, Center of Biomolecular & Nanoscale Engineering for Targeted Therapeutics (BioNETT), Case Comprehensive Cancer Center and Department of Biomedical Engineering (BME), Jinming Gao, Ph.D. Co-Director. Supported by a Case Presidential Research in Excellence Award to Biomedical Engineering, CWRU, Cleveland, OH.
May, 2003-June 30, 2005.
Co-Director, Translational Research Core (TRC), Case Comprehensive Cancer Center, Co-Director, Paul Hartman, Case Comprehensive Cancer Center,
September, 1998-May, 2005.Co-PI, Aging and Cancer Training Grant, Dept. of Pathology,
Confidential Page 3 4/8/2023
3
September 2001-May, 2005.Principal Investigator, American Cancer Society Pilot Grant Program, Case Comprehensive Cancer Center, Cleveland
August, 2004-May, 2005.
Full Professor, University of Texas Southwestern MedicalAssociate Director Center, Departments of Oncology, Pharma-For Translational cology, and Radiation OncologyResearch Simmons Comprehensive Cancer Center,
ND-2, 5323 Harry Hines Blvd. Dallas, TX 75390-8590,
June 1, 2005-Present
Robert B. and Virginia University of Texas Southwestern Medical Payne Professor of Center at Dallas, Simmons ComprehensiveOncology Cancer Center
July 1, 2005-Present
Co-Director, Cell Stress & Simmons Comprehensive Cancer Center Cancer Nanomedicine University of Texas Southwestern Medical
Center at Dallas (Dr. Jinming Gao, co-Director)July 1, 2005-Present
Other Associations At UTSWTrainer, Cancer Biology Training Grant,
September, 2005-Present.Trainer, Genes and Development, September, 2005-Present.Trainer, Pharmacology Graduate Program,
September, 1998-Present.Trainer, Genetics Training Grant,
March, 2007-Present.
INSTITUTIONAL LECTURES At University of Michigan:
Department of Radiation Oncology Colloquium Series, “Role of X-ray-inducible proteins in adaptive survival responses”, December 12, 1990.
Comprehensive Cancer Center Colloquium, “Use of X-ray-responsive promoters for gene therapy”, May, 1991.
Department of Pharmacology Lecture Series, “Role of DNA Topoisomerase I in DNA repair”, May 12, 1992.
Department of Radiation Oncology Lecture Series, “Isolation of X-ray-inducible proteins and transcripts”, October 14, 1992.
Comprehensive Cancer Center Colloquium, “Use of X-ray-responsive promoters for gene therapy”, May, 1991.
Confidential Page 4 4/8/2023
4
At University of Wisconsin:Department of Human Oncology Colloquium Series, “Role of Topoisomerase
I In DNA Repair”, October 1, 1994.UWCCC Grand Rounds, “Alterations In Gene Expression After X-Rays: Clinical
Applications”, October 5, 1994.UWCCC-Department of Human Oncology Colloquium Series, “Modulation of
Retinoblastoma Control Proteins After Ionizing Radiation: Molecular Sensors of DNA Damage”, October 26, 1994.
University of Wisconsin Comprehensive Cancer Center Breast Cancer Program, “Use of ß-Lapachone Derivatives For Breast Cancer Therapy”, April 12, 1995.
Joint University of Wisconsin Comprehensive Cancer Center-Agracetus, Inc. Gene Therapy Meeting. “Role of the Fanconi’s anemia group C gene in apoptosis caused by the topoisomerase I inhibitors, ß-lapachone and camptothecin”. (Hosts: Drs. Yang and Sondel) September 8, 1995.
Genomic Instability Group, “Use of ß-lapachone and other topoisomerase I inhibitors for chemotherapy against human prostate and breast cancers” (Investigators involved: Drs. Timothy J. Kinsella (DHO), Catherine Reznikoff (DHO), Mark Ritter (DHO), Mary Ellen Perry (Oncology), John Petrini (Medical Genetics), and David A. Boothman (DHO), and their respective graduate students, technicians and post-doctoral fellows. January 1995-February, 1997.
UWCCC-Human Oncology Colloquium Series, “Role of DNA mismatch repair in G2/M cell cycle arrest”, January 30, 1997.
UW School of Pharmacy, University of Wisconsin-Madison, “Role of DNA mismatch repair In G2/M cell cycle arrest”, February 25, 1997.
UW Department of Pharmacology, “Topoisomerase I-mediated apoptosis in human cancer cells”, May 13, 1997.
UW Department of Neurological Surgery, “Apoptotic responses in human tumor cells: a novel noncaspase-mediated pathway”, October 16, 1997.
Wisconsin Cancer Registry, “Genetics and environmental factors which influence cancer”, October 23, 1997.
UW Department of Pharmacology, “Role of the MLH1 DNA mismatch repair protein in G2/M cell cycle checkpoint regulation in response to FdUrd exposure, March 19, 1998.
At Case Western Reserve University:Invited Speaker, Case Western Reserve University Comprehensive Cancer
Center Annual Retreat, “X-ray-inducible proteins, DNA Repair, and Apoptosis”, For Symposium: “Hormone-Responsive Malignancies”, Mohican State Park Conference Center, September 17-18, 1998.
Invited Speaker, Chemoprevention Conference, CWRU Ireland Comprehensive Cancer Center. “Exploiting an X-ray-inducible gene product for
Confidential Page 5 4/8/2023
5
chemoprevention by ß-lapachone” Manakiki Golf Course and Country Club, October 9, 1998.
Discussion Leader, Pharmacology Retreat, Mohican State Park Conference Center, November 8-9, 1998.
Discussion Leader, Preclinical Basic Research and Translational Studies, CWRU Comprehensive Cancer Center. “Preclinical Investigations” November 17, 1998.
Invited Speaker, DOD Prostate Cancer Initiative Applications, “Potential use of ß-lapachone for use against prostate cancers”. CWRU Ireland Comprehensive Cancer Center. January 20, 1999.
Invited Speaker, “Exploiting X-ray-inducible gene products for chemotherapy: A novel apoptotic response” Ion and Apoptosis Discussion Group, February 25, 1999.
Invited Speaker, Ireland Comprehensive Cancer Center Blood Club Symposium, “Understanding and exploiting stress proteins for therapy against human breast cancer” April, 1999.
Co-organizer, Ireland Comprehensive Cancer Center Retreat, Mohican State Park, Chaired session entitled “DNA Repair and Cell Cycle Regulation”, October 7-8, 1999.
Session Chairman, Department of Pharmacology Annual Retreat, “Apoptosis” , October 21-22, 1999.
Invited Speaker, Translational Research Grant Monthly Seminars, 'Exploiting stress-inducible responses for human cancer therapy', February 24, 2001.
Invited Speaker, "Use of ß-lapachone for therapy against breast, prostate and lung cancers. Phase I Meeting, Experimental Therapeutics, Ireland Comprehensive Cancer Center, Nov. 12, 2001.
Invited Speaker, "Imaging stress-inducible proteins exploited for cancer therapy", Imaging Group, Ireland Comprehensive Cancer Center, Nov 21, 2001.
Invited Speaker, "ß-lapachone: a kiss of death" Blood Club, February 21, 2002.Invited Speaker, “Clusterin: a molecular switch between life and death” Dept.
Cell and Mol Biol, CWRU, (Host: Alan Tartakov, Ph.D.) October, 2003.Invited Speaker, “Signal transduction pathways controlling clusterin expression
after ionizing radiation” Cleveland Clinic Foundation, September, 2004.Invited Speaker, “A novel calcium-dependent necroptotic response induced by
ß-lapachone”. CWRU Blood Club, November, 2004.Invited Speaker, “Involvement of clusterin responses in replicative senescence”
January 4, 2005.Invited Speaker, “The clusterin stress-inducible response gene: A life or death
response” MetroHealth Hospitals of Cleveland, February 15, 2005.Invited Speaker, “Use of ß-lapachone against human prostate cancers that
express elevated NQO1 levels.” Department of Urology, March, 2005.
At University of Texas Southwestern Medical Center:
Confidential Page 6 4/8/2023
6
Speaker, “Clusterin: a damage-sensitive inducible promoter”, CIP Imaging Center, Host: Ralph Mason, September, 2005.
Speaker, “ß-Lapachone-induced apoptosis”, B & B Pharmacology, October, 2005.
Speaker, “ß-Lapachone: a kiss of death”, First Annual Simmons Comprehensive Cancer Center Retreat, October, 2005.
Speaker, “KUB5: a gene involved in blunt DNA double strand break repair”, DNA Double Strand Break Repair Working Group, DNA Damage and Repair Program, UTSW Cancer Center. February 10, 2006.
Speaker, “Role of DNA mismatch repair in G2 arrest and apoptosis”, DNA Damage and Repair Program, UTSW Cancer Center. February 21, 2006.
Speaker, “NQO1 bioactivatable drugs for treating lung cancer” Breast Cancer Working Group, Simmons Comprehensive Cancer Center, September 18, 2006.
Speaker, “ß-Lapachone anti-tumor activity: a KISS of death” Cancer and Chemistry PPG Working Group, September 22, 2006.
Speaker, “Exploiting inducible NQO1 levels for improved therapy” Hammon Center for Cancer Research, Simmons Cancer Center, October 12, 2006.
Speaker, “Exploiting stress-inducible gene expression for improved cancer therapy”. Angiogenesis Working Group, October 20, 2006.
Speaker, “Use of ß-lapachone against nonsmall cell lung cancer” CIP Imaging Center, Hosts: Ralph Mason and Dean Sherry, November, 2008.
Speaker, “Stress-inducible responses”, Cancer Biology Training Grant Dinner Seminar Series, March, 2009.
NATIONAL AND INTERNATIONAL LECTURESInvited Speaker, American Association of Cancer Research, Student Research
Award, April, 1985.Invited Speaker, European Environmental Mutagen Society, XVIII Annual
Meeting, Varna, Bulgaria, October, 1988. Invited Speaker, Fifth International Conference on Environmental Mutagens,
Molecular Aspects", Lake Tahoe, CA, January, 1990.Invited Speaker, Radiation Research, "DNA Damage-Inducible Responses In
Mammalian Cells", New Orleans, LA, April, 1990.Invited Speaker, Gordon Conference, "DNA Damage-Inducible Responses In
Mammalian Cells", New London, NH, July, 1990.Invited Speaker, Syracuse University RUNN Symposium, Woods Hole, MA,
Nov. 4-11, 1990.Visiting Professor, Argonne National Laboratories, Biological and Medical
Research Division, Argonne, IL, January, 1991.Visiting Professor, University of Miami, Department of Radiation Oncology,
Miami, Fla., February, 1991.Visiting Professor, Lawrence Berkeley Laboratory Seminar Series, Division of
Radiation Oncology, Berkeley, CA, February, 1991.
Confidential Page 7 4/8/2023
7
Invited Speaker, .Yokohama City University, School of Medicine , Department of Radiation Biology, Yokohama, Japan, March 8-15, 1991.
Invited Speaker, 3rd International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, "Il Cocco", Lucca, Italy, May, 1991.
Invited Speaker, 9th International Congress of Radiation Research, Workshop on "Radiation-induced gene expression", Toronto, Canada, July, 1991.
Invited Reviewer, National Cancer Institute, Dept. Health & Human Services, Radiation Effects Branch, (FY92 RFA), Workshop on "Ionizing Radiation-Induced Genes and Proteins" Bethesda, MD., September, 1991.
Invited Speaker, American Cancer Society, Michigan Division, Michigan Cancer Research Conference, Meyer L. Prentiss Comprehensive Cancer Center, Detroit, Michigan, September 20, 1991.
Invited Speaker, Department of Pharmacology, Miniseries on Chemotherapy, University of Michigan, Ann Arbor, MI, January 15, 1992.
Chairman, Radiation Research Society, Directed and gave the opening Seminar on "Temporal Changes In Gene Expression Following Ionizing Radiation: Early and Late Consequences", 40th Ann. Mtg. Radiation Research Society, Salt Lake City, Utah, March 13-18, 1992.
Chairman and Invited Speaker, "International Conference on Low Dose Irradiation and Biological Defense Mechanisms", International Atomic Energy Agency, (Prof. Takashi Aoyama, Sec. General) Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga 520-21, Japan, July 12-15, 1992.
Invited Speaker, Department of Pharmacology, Nagasaki University, Nagasaki, Japan, July 16, 1992.
Invited Speaker, "Changes In Gene Expression Following Ionizing Radiation", Host: Elwood P. Armour, William Beaumont Hospital, Royal Oak, MI, December 2, 1992.
Chairman, "Molecular Biology Techniques Applied To Radiobiology" Radiation Research Society, Dallas TX, March 20-25, 1993
Invited Speaker, "DNA Repair Responses Following Ionizing Radiation", Ontario Cancer Inst./Princess Margaret Hospital, Ontario, CA, April 29, 1993.
Invited Speaker, "Down-regulation of topoisomerase I correlates with increased DNA repair following ionizing radiation". 84th Annual Meeting of the American Association for Cancer Research. Minisymposium Orlando, FL, May 19, 1993.
Invited Speaker, "Isolation of X-ray-inducible transcripts: potential role of newly synthesized genes and proteins in adaptive survival responses and DNA repair". Plenary talk, 84th Annual Meeting of the American Association for Cancer Research. Orlando, FL, May 21, 1993.
Chairman and Invited Speaker, The 40th Harden Conference on "Regulation of Gene Expression by Oxidative Stress; Implications for Health and Disease", The Scottish Highlands, Nethybridge, Inverness-shire, Scotland, August 29-September 6, 1993.
Invited Speaker, "Role of X-Ray-Inducible Genes and Proteins In Adaptive Survival Responses." International Symposium on Biological Effects of Low
Confidential Page 8 4/8/2023
8
Level Exposures To Radiation and Related Agents (Isbelles, '93), Changchun, China, October 12-16, 1993.
Invited Speaker, "Changes in Gene Expression Following Ionizing Radiation", Los Alamos National Laboratories, Department of Molecular Biology, November 3-5, 1993.
Invited Speaker, Radiation Study Section Workshop on "Problems To Be Solved In Ionizing Radiation-Inducible Gene/Proteins Produced By Mammalian Cells" Taos, New Mexico, February, 1994.
Invited Speaker, “ADP-ribosylation of Topoisomerase I Is Required For DNA Repair: Modulation of Topo I Increases X-Ray Lethality” 85th Annual Mtg. American Assoc. for Cancer Research, San Francisco, CA. April 9, 1994.
Invited Speaker and Chairman, Poster Discussion Session “Induced Gene Expression” 85th Annual Mtg. American Association for Cancer Research, San Francisco, CA. April 9, 1994.
Invited Speaker, "Alterations in Cell Cycle Progression Determine Adaptive Survival Responses to Ionizing Radiation" Symposium on DNA Repair, McGill University, Montreal, Canada. June 3-4, 1994.
Invited Speaker, “Coupling of Inducible Transcripts and Cell Cycle Progression as Determinants of Radioresistance” 22nd Annual Mtg. American Society for Photobiology, Scottsdale, Arizona. June 25-29, 1994.
Invited Speaker, “Coupling of Transcription, Cell Cycle Progression, and DNA Repair Determines Radiosensitivity”, Fourth Research Workshop on the Biology, Prevention, & Treatment of Head and Neck Cancer, Arlington, Virginia. Sept. 8-11, 1994.
Invited Speaker, “Adaptive Survival Responses In Human Cells” Pacific Northwest Laboratories, Sponsor: DOE, Dr. Les Braby, Richland, WA, October 10-12, 1994.
Chairman and Invited Speaker, “Molecular Mechanisms in X-ray-inducible Transcription and Their Involvement in Cell Cycle Regulation”, Radiation Biology Center 12th International Symposium on “Gene Regulation and Cellular Responses to Radiation”, Kyoto, Japan. November 20-27, 1994.
Invited Speaker, “Coupling of DNA Repair to Transcription: Adaptive Survival Mechanisms” Medical College of Wisconsin, Department of Radiation Oncology & Medical College of Wisconsin Comprehensive Cancer Center, (Host: Jeffrey Shadley, Ph.D.), January 25, 1995.
Invited Speaker, Gordon Research Conference, “Mammalian DNA Repair Mechanisms” (M. Smerdon, coordinator), Ventura, CA Jan. 29 -Feb. 3, 1995.
Invited Speaker, “Radiation Responses In Human Cells After Ionizing Radiation”, Henry Ford Hospital, (host: Jae Ho Kim, M.D., Ph.D.), Detroit, Michigan, February 8, 1995.
Invited Speaker, “Coupling of DNA Repair and Transcription After Ionizing Radiation”, University of Pennsylvania, (Host: Craig Stevens, Ph.D.), February 15, 1995.
Invited Speaker, “Sp1 Activation: A Nuclear Transcriptional Sensor of DNA Damage”, American Health Foundation. (Host: Zeev Ronai, Ph.D.), Valhalla, NY, February 27-28, 1995.
Confidential Page 9 4/8/2023
9
Invited Speaker, “Use of X-ray-responsive Promoter Elements In Gene Radiotherapy”, University of Alabama, Department of Radiation Oncology, Birmingham, Alabama, (Host: Donald J. Buchsbaum, Ph.D.), March 1-3, 1995.
Invited Speaker, “Altered Cell Cycle Regulation and Topoisomerase I Down-regulation After Radiation Affect DNA Repair” University of California San Francisco, (Host: Robert M. Stroud, Ph.D.), April 27, 1995.
Symposia Chair and Organizer, “X-ray-inducible Genes/Proteins: Signals of Induction and Proposed Functions” Radiation Research Society, San Jose, CA, April 4, 1995.
Invited Speaker, “Modulation of Retinoblastoma Control Proteins By Ionizing Radiation” Radiation Research Society, San Jose, CA, April 4, 1995.
Invited Speaker, National Cancer Institutes Cancer Center Public Relations Conference, UWCCC. May, 1995.
Invited Speaker and Session Chairman, “Retinoblastoma Control Proteins, Sp1, p53, and NF-kB: Sensors of DNA Damage In Mammalian Cells”. The National Japanese Tissue Culture Association, Nagasaki, Japan. May, 1995.
Invited Speaker and Symposium Chair, “Altered Gene Expression and Cell Cycle Regulation Determine Adaptive Survival Responses” 10th Internal. Radiation Research Congress, Wurzburg, Germany. August, 1995.
Invited Speaker and Session Chairman, “Adaptive Survival Responses In Human Cells”, Satellite meeting on Low Dose Radiation Effects, Wurzburg, Germany. September, 1995.
Invited Speaker, “Changes in Gene Regulation After Ionizing Radiation” International Conference on “Low Dose Radiobiological Mechanisms and Human Health Effects”. Sponsor: Bhabha Atomic Research Centre, Government of India, Dr. P.S. Chauhan, Head Cell Biology Division, Bombay, India, January 15-18, 1996.
Invited Speaker, “Effects of Low Dose Ionizing Radiation on Human Cells” 10th Anniversary, Chernobyl Accident, Host: Dr. Nick Dainiak, Chairman, Bridgeport Hospital, Belarus. March 19-30, 1996.
Session Chairman, “Radiation-induced Apoptosis”, 10th Anniversary, Chernobyl Accident (Host: Dr. Nick Dainiak), Chairman, Bridgeport Hospital, Belarus, March 19-30, 1996.
Invited Speaker, “Alterations in Transcription, Gene Expression, Apoptosis, Cell Cycle Regulation, and Topoisomerase I Function After Low and High Doses of Ionizing Radiation”. Institute of Cytology, University of St. Petersburg, Russia (Host: Dr. A. Parfenov), Chairman and Director, Institute of Cytology. March 28, 1996.
Invited Speaker, “Sensors of DNA Damage” Radiation Research Society, Symposium on gene induction after DNA damage. Chair: Gayle Woloschak, Ph.D.; Chicago, Il, April 14, 1996.
Invited Speaker, “Role of topoisomerase I in DNA repair and use of inhibitors for chemotherapy” (Host: Andy Grosovsky), University of California at Irvine, May 11-15, 1996.
Confidential Page 10 4/8/2023
10
Invited Speaker, “ß-Lapachones: new topoisomerase I inhibitors that are active against human breast and prostate cancers” (Host: Richard Fishel), Thomas Jefferson University, Philadelphia, PA, August 19-21, 1996.
Invited Speaker, “Molecular Biology of Radiation Resistance” ECOG Meeting, Miami, Florida, October 1-2, 1996.
Invited Speaker, “Studies on a cell line from a patient with Fanconi anemia-like syndrome”, Eighth Annual International Fanconi Anemia Scientific Symposium, Madison, Wisconsin, October 10-12, 1996.
Invited Speaker, “Low dose rate effects on gene expression in human cells”, University of North Carolina, Research Triangle Park, NC, Nov. 12-14, 1996.
Invited Speaker, “Activation of retinoblastoma control proteins after ionizing radiation” University of Florida (Host: Dietmar W. Siemann), Gainesville, Fla, Dec. 10-12, 1996.
Invited Speaker, “ß-Lapachone-mediated apoptosis in human breast cancer” (Host: Mitra Gopa), Promega, Inc., Madison, WI. Dec. 13, 1996.
Invited Speaker, “Topoisomerase I-mediated apoptotic responses in human breast Cancer cells”, University of Indiana School of Medicine, Indianapolis, Indiana, Dec. 15-18, 1996.
Invited Speaker, “Synergistic responses between radiation and topoisomerase I poisons” Radiation Research Society Annual Meeting, Providence, Rhode Island, May 3-5, 1997.
Invited Speaker, “Topoisomerase I-mediated apoptosis in human prostate cancer” CaPCure Annual Meeting, Lake Tahoe, CA, Sept. 2-4, 1997.
Invited Speaker, “Apoptosis from nuclear signals”, University of Pittsburgh, Department of Pharmacology, Host: Qing-Ping Dou, September 24-25, 1997.
Invited Speaker, “Role of DNA mismatch repair in G2/M cell cycle arrest”, Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, December 14-16, 1997.
Invited Speaker, “Role of NF-kB in apoptotic responses in human prostate cancer cells following topoisomerase I poisons ”, Case Western Reserve Prostate Cancer Symposium, December 14-16, 1997.
Invited Speaker, “XIP8, a Ku70-binding protein”, University of Cincinnati, Department of Biochemistry (Host: Dr. Judy Harmony), March, 1998.
Invited Speaker, “ß-Lapachone-mediated apoptosis”, University of Chicago, Department of Pharmacology, Host: Eileen Dolan, May, 1998.
Keynote Speaker and Session Chair, “XIP8, an X-ray-inducible Ku70 DNA binding protein that down-regulates DNA repair and induces apoptosis” 2nd Wolfsberg Meeting on Molecular Radiation Biology/Oncology, Wolfsberg Castle, Ermatingen, Switzerland (H. Peter Rodemann, Ph.D., coordinator), June 18-25, 1998. (Also invited as a judge for Poster presentations).
Invited Speaker, “Role of hMLH1 in G2/M cell cycle arrest”. 27th Annual Meeting, American Society for Photobiology, Snowbird, Utah, July 11-15, 1998.
Keynote Speaker and Meeting Coordinator, “X-ray-inducible responses in human cells” 1998 Gray Conference entitled “Molecular stress responses,
Confidential Page 11 4/8/2023
11
cancer therapy and radiation injury”, University of York, York, England, (J.V. Moore, organizer), Sept. 4-8, 1998.
Invited Speaker, “X-ray-inducible genes and proteins in adaptive survival responses”, National Institutes of Environmental Health Services (NIEHS), Special Conference: “Societal Implications of Hormesis”, Coordinator: Dr. Edward J. Calabrese, Research Triangle, NC, October 27, 1998.
Invited Speaker, “Exploiting X-ray-inducible responses for improved therapy” Northern Illinois University, (Host: Dr. John Mitchell); Student’s Choice Lecturer. Feb. 4-6, 1999.
Invited Speaker, “Nuclear apoJ/XIP8, an X-ray-inducible Ku70 binding protein which triggers cell death. Gordon Research Conference on “ApoE, Clusterin (apoJ)”. Jan. 22-27, 1999.
Invited Speaker, “Nuclear apoJ/XIP8, a Ku70 binding protein”. Gordon Research Conference on “DNA Repair”. Feb 7-12, 1999.
Invited Speaker, Exploiting IR-inducible Proteins For Therapy Against Breast Cancer, Midwest DNA Repair Conference, Ann Arbor, Michigan, June 13, 1999.
Invited Speaker, “Exploiting X-ray-inducible proteins for apoptotic chemotherapy” Essen, Germany (Host: C. Streffer) July 14-17, 1999.
Invited Speaker, “Nuclear XIP8, an X-ray-inducible death signaling protein that binds Ku70”. 11th International Congress of Radiation Research, University College Dublin, Ireland, July 18-23, 1999.
Invited Speaker, “A novel noncaspase-mediated apoptotic pathway induced by ß-lapachone: involvement of NQ01”, Department of Radiation Oncology, University of Maryland, (Host: W.F. Morgan) October 23, 1999.
Invited Speaker, “Nuclear apoJ/XIP8, a low dose IR-inducible cell death trigger” Department of Health and Human Services, National Institute on Aging, Gerontology Research Center, (Host: M. Evans), September 24, 1999.
Session Chairman, DOE Workshop on Low Dose Irradiation Effects, “Altered gene expression after low doses of ionizing radiation” Germantown, MD, November 11,1999.
Invited Speaker, "Exploiting novel apoptotic pathways", Cleveland Clinic Lerner Research Institute. (Host: A. Almasan) November, 1999.
Invited Speaker, New York Academy of Sciences Symposium, entitled “The camptothecins: unfolding their anticancer potential”, Arlington, Virginia, March 17-20, 2000.
Invited Speaker and Session Chairperson, 43rd Annual Meeting of Radiation Research, "Altered gene expression after ionizing radiation", Alburquerque, MN. April 24-28, 2000.
Invited Speaker, DOD Symposium on Breast Cancer Initiative. Seminar entitled “ß-Lapachone triggers NQ01-dependent apoptosis in human breast cancer cells by activating a calcium-dependent noncaspase cysteine protease.” Atlanta, GA, June 11-12, 2000.
Invited Speaker and Session Organizer, 13th International Congress on Photobiology, “Nuclear CLU/XIP8, an x-ray-induced Ku70 binding protein that signals cell death” San Francisco, CA, July 1-6, 2000.
Confidential Page 12 4/8/2023
12
Invited Speaker, "Exploiting IR-inducible responses for chemo- and/or radiotherapy" Department of Pharmacology, University of Pittsburgh, Host:Dr. Jack Yalowich. November 9-10, 2000.
Invited Speaker, NIH Workshop: "Probing Individual Cells: Applications to Signaling, Structure and Function", seminar entitled 'Inducible Clusterin: a two-faced protein", Sponsors: NIH/NCI (Hosts: Drs. Dick Pelroy and David Brenner), Washington, DC, March 13, 2001.
Minisymposium Chairman, "X-ray-inducible proteins", AACR Annual Meeting, New Orleans, LA, March 24-28, 2001.
Invited Speaker, 2nd Annual Experimental Therapeutics Conference. "Nuclear clusterin: a taxane- and IR-inducible protein and marker of apoptosis", Joint Pitts/CWRU Conference, Pitts., PA, July 27, 2001.
Invited Speaker, "Exploiting IR-inducible gene expression for breast cancer therapy." Department of Pharmacology, University of Wisconsin-Madison (Host: Dr. Shigeki Miyamoto), December 4, 2001.
Invited Speaker, "A novel apoptotic pathway induced by ß-lapachone", Medical College of Wisconsin, Milwaukee, WI December 5, 2001.
Invited Speaker, "Exploiting IR-inducible proteins for radio- and chemo-therapy". NIH/DOD/NASA/DOE Interagency Workshop, N. Coleman, Director, "What happens when a dirty nuclear bomb explodes in a big city? December 16-18, 2001.
Invited Speaker, "Exploiting stress responses for improved chemo- and radio-therapy", Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Fla., (Host: Dr. Sheldon Greer), Jan. 24-25, 2002.
Invited Speaker, "Ionizing radiation-inducible clusterin (CLU), a molecular switch between life and death". Reno, Nevado, April 25-27, 2002.
Invited Speaker, "Use of sCLU expression as a biomarker for low dose radiaiton or cytotoxic drug exposures". EPA meeting, Washington DC, Dick Bull, Ph.D. organizer, July, 2002.
Invited Speaker, “Clusterin expression as a biodosimeter”. Nagasaki University, Nagasaki, Japan. February 16-24, 2003.
Invited Speaker, “ ß-lapachone: A kiss of death”. University of South Florida, Tampa, Florida, Host: Kapil Bahla, March 25-26, 2003.
Invited Speaker, “ Role of DNA mismatch repair in FdU- and low Dose IR detection and repair of damage”. Genetic and Environmental factors affecting human colon cancer” EMS Satellite Meeting. Miami Fountain Blue Conference Center, Miami Beach, Florida, May 12-13, 2003.
Invited Speaker, “Clusterin gene expression: a sensitive measure of ionizing radiation and drug exposure” Environmental Mutagenesis Society, Miami, Florida, May 14, 2003.
Workshop Organizer, DOE Workshop, “Bystander effects after low doses of IR”, Wash., DC, October, 2003.
Invited Speaker, “Ionizing radiation-inducible stress responses and their interface with DNA repair” Molecular Radiation Biology Workshop, Munich, Germany, November, 2003.
Confidential Page 13 4/8/2023
13
Invited Speaker, “ß-lapachone: a calcium-dependent killer”. University of Wisconsin-Madison, (Host: Shigeki Miyamoto, Ph.D.), September, 2004.
Invited Speaker, “Clusterin: a gene determining cell death and survival” Cleveland Clinic Foundation (hosts: Bryan Williams, Ph.D. and Alex Almasan, Ph.D.), October, 2004.
Invited Speaker, “Clusterin: a determinant of cell death and survival.” University of Texas Southwestern, (Host: Hak Choy, MD), November, 2004.
Invited Speaker, “Clusterin: a regulatory cell death protein”, Roswell Park, Buffalo, NY, (Hosts: Michael Brattain, Ph.D. and Carl Porter, Ph.D.), December, 2004.
Invited Speaker, “Exploiting NQO1 for improved therapy of cancer using ß-lapachone” University of Minnesota, Minneapolis, MN, December, 2004.
Invited Speaker, “Clusterin: a life and death decision-making gene”, (Host: Dr. Andrei Thomas-Tikhonenko) University of Pennsylvania,, Philadelphia, PA, January 12, 2005.
Invited Speaker, “Clusterin gene expression: a molecular decision-making gene between life and death” MetroHealth Foundation, February 15, 2005.
Invited Speaker, “Use of clusterin gene expression responses as a biosensor for radiation and chemical exposures”. Workshop on Biodefense, NIH and DOD, February 20, 2005.
Invited Keynote Speaker, 4th International Symposium on Clusterin, “Regulatory processes controlling clusterin gene expression.” Swtizerland, June 12-17, 2004.
Invited Keynote Speaker, 4th International Symposium on Clusterin, “Nuclear clusterin revealed: synthesis and activation of a pro-death gene.” Swtizerland, June 12-17, 2004.
Invited Speaker, “Role of DNA Mismatch Repair in MNNG-induced DNA lesions” EMS Satellite Meeting on DNA lesion detection, Portland, ORE, September 9-12, 2005.
Invited Speaker, “ß-Lapachone antitumor activity: A kiss of death” Department of Molecular Imaging (Host: Dr. W. Bornmann, M.D.), MD Anderson, Houston, TX, March 21, 2006.
Invited Speaker, “Regulation of IGF-1 after low dose ionizing radiation” Fifth international symposium for low dose ionizing radiation effects research” (Host: Dr. Masami Watanabe), Nagasaki University, July 23-30, 2006.
Invited Speaker, “Low dose-inducible IGF-1 responses: regulation by p53 and Hdm2” DOE Low Dose Workshop, August 1-3, 2006.
Invited Speaker, “Exploiting stress-inducible protein responses for improved therapy of human cancer” (Host: David Cheresh, Ph.D.) University of California San Diego. August 17, 2006.
Abstract Program Committee, “DNA Damage and Repair”. American Association for Cancer Research 100th Annual Meeting, UCLA, April 12-16, 2007.
Invited Speaker, “The role of µ-calpain in ß-lapachone-induced lethality” Annual FASEB meeting, Snowmass, Colorado, July 14-19, 2007.
Confidential Page 14 4/8/2023
14
Invited Speaker, “The insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) induction pathway” Columbia University, (Host: David Brenner, Ph.D.) RARAF, February 2-5, 2008.
Invited Speaker, “Induction of the IGF-1-sCLU pathway by transforming growth factor-beta1: roles in metastatic spreading after low doses of ionizing radiation (IR)”. Nagasaki University Center of Excellence Program, January 30-February 3, 2008.
Invited Speaker, Regulation of secretory clusterin by the IGF-1 pathway, Institute of Biological Research & Biotechnology, National Hellenic Research Foundation, University of Athens, Greece, (Host: I. Trougakous, PhD), June 4, 2008.
Keynote Speaker, The 5th International Clusterin Conference, “Regulation and function of secreted clusterin”, (I. Trougakous, PhD and S. Gonos, PhD, Conference Organizers), Spetses Island, Greece, June 5-8, 2008.
Invited Speaker, “The stress-induced IGF-1-sCLU pathway during cellular senescence”, Institute of Biological Research & Biotechnology, National Hellenic Research Foundation, University of Athens, Greece, (Host: S. Gonos, PhD), Santorini, Greece. June 9, 2008.
Invited Speaker, “Expression of IGF-1-sCLU as a measure of genetic instability, EMT responses and a mediator of metastases” University of Michigan Cancer Center and Department of Radiation Oncology, (Host: Ted Lawrence, MD) Univ. Michigan, Ann Arbor, MI. July 25, 2008.
Invited Speaker, “Regulation of the insulin-like growth factor-1-secretory clusterin (IGF-1-sCLU) pathway as a marker of genetic instability and function in tumor metastases”, (Host: Martin Gleave, M.D., Ph.D.), University of Vancouver, December 4-6, 2008.
Invited Speaker and Co-organizer, “Regulation of the insulin-like growth factor-1-secretory clusterin (IGF-1-sCLU) pathway as a marker of genetic instability and function in tumor metastases”, (Host: M. Watanabe, PhD), Kumatori Symposium, Osaka University and Kyoto University, Health Research Foundation, December 16-20, 2008.
Invited Speaker, “The ATM-IGF-1-sCLU expression pathway and its importance in senescence and metastases”, The DNA Repair Seminar Series, (Host: B. Sleckman, MD, PhD), Washington University, April 6, 2009.
Invited Speaker, “The IGF-1-sCLU expression axis: sensitive indicator of reactive oxygen species damage”. “Clusterin; In health and disease”. Sixteenth Annual Glaucoma Foundation Optic Nerve Rescue and Restoration Think Tank. EXFOLIATION SYNDROME: THE FIRST POTENTIALLY CURABLE GLAUCOMA. New York, October 2-3, 2009.
Invited Speaker, “Use of ß-lapachone micelles for radiosensitization of nonsmall cell lung cancers” Radiation Biology Gordon Research Conference, Galveston, TX, January 24-29, 2009.
REVIEWER FOR SCIENTIFIC JOURNALSBiomedical Biophysical Research CommunicationsBritish J. of CancerCell
Confidential Page 15 4/8/2023
15
Cancer Biology and Therapy (Editorial Board)Cancer LettersCancer ResearchEMBO J.FASEB J.GastroenterologyInternational J. of Cancer ResearchInternational Journal of Radiation Oncology, Biology, & PhysicsInternational Journal of Radiation BiologyInternational J. of Oncology (Associate Editor, 1996-Present)Journal of Biological ChemistryJournal of Cellular PhysiologyMolecular & Cellular BiologyMolecular CellMolecular PharmacologyMutation ResearchNatureNature Cell BiologyNature GeneticsNucleic Acids ResearchOncology (Associate Editor, 1994-1999)Oncology Reports (Associate Editor, 1995-1999)Radiation Research (Associate Editor, 1993-1995)Proceedings of the National Academy of Sciences, USAScience
GRANT SUPPORT
Past Support (Funded Grants Written by the Candidate):1. Biomedical Research Support Grant, NIH. "Anticarcinogenesis testing
using Topoisomerase I active Drugs", P.I.: Arthur B. Pardee, Ph.D., $15,000 for one year, ended Feb. 29, 1988.
2. Biomedical Research Support Grant, NIH. "Molecular Cloning of X-Ray-induced genes", P.I.: Arthur B. Pardee, Ph.D., $15,000 for one year, ended March 1, 1988.
3. Biomedical Research Support Grant, ACS. "X-Ray-Inducible Genes and Proteins In Cancer-prone Compared To Normal Human Cells", P.I.: David A. Boothman, Ph.D., $30,000 from May 1, 1989 to April 31, 1990.
4. Milheim Foundation, "Role of Topoisomerase I In DNA Repair", P.I.: David A. Boothman, Ph.D. (20% salary), $15,000 from July 1, 1990 to June 30, 1991.
5. National Institutes of Health, "Use of Topoisomerase I Inhibitors For Chemotherapy", P.I.: Arthur B. Pardee's NIH grant, I was a consultant on that grant for $10,000 from 1991-1992, 0.0% salary.
6. American Cancer Society, PDT-413/DHP-90A, "Role of Topoisomerase I In DNA Repair", P.I.: David A. Boothman, Ph.D. (20% salary), $300,000 from July 1, 1991 to June 30, 1995.
Confidential Page 16 4/8/2023
16
7. Department of Energy, DE-FG02-93ER61707-01-03, "Role of X-Ray-Induced Transcripts In Adaptive Survival Responses Following X-Rays", P.I.: David A. Boothman, Ph.D. (35% salary), $459,196 from Sept. 28, 1991 to October 31, 1994.
9. American Cancer Society, EDT-45 “Molecular Cloning Of X-Ray-Induced Genes and Proteins: Induction of Transcriptional Machinery", P.I.: David A. Boothman, Ph.D. (20% salary), $300,000 from Jan. 1, 1991 to Dec. 31, 1995.
10. University of Wisconsin Comprehensive Cancer Center, DeMerrit Foundation Grant, "Gene Radiotherapy Using X-Ray-Responsive Elements", P.I.: David A. Boothman, Ph.D. (0% salary), $15,000, Jan. 1, 1993 to Dec. 31, 1994.
11. National Institutes of Health (RO1), "Cloning an X-Ray-Induced Protein In Radioresistant Cells", P.I.: David A. Boothman, Ph.D. (20% salary), $360,000 for 3 years, Sept. 28, 1992 to Sept. 27, 1996.
12. Clarion Pharmaceuticals, “Use of compound, CPR1006, to augment radiation therapy”, P.I.: David A. Boothman, Ph.D. (0% salary), $10,000 pilot grant with future funding available depending upon results.
13. Department of Energy, DE-FG02-93ER61707-03-06, "Role of X-Ray-Induced Transcripts and Altered Cell Cycle Regulation In Adaptive Survival Responses Following X-Rays: Potential Role of Mismatch, Excision, and Recombinational DNA Repair Systems", P.I.: David A. Boothman, Ph.D. (35% salary), $579,485 for 3 years, Oct. 31, 1994 to Nov. 1, 1997.
14. Breast Cancer Fund, “Use of ß-lapachone and its derivatives against human breast and prostate cancers”. P.I.: David A. Boothman, Ph.D. (0% salary), $22,000/yr for 1 year to fund the initial human breast and prostate cancer xenograft nude mouse testing of key ß-lapachone derivatives.
15. CapCure Foundation, “Topoisomerase I-mediated apoptosis in human prostate cancer cells”. P.I.: David A. Boothman, Ph.D. (0% salary), $75,000 for 1 year, 02/01/97. Discretionary gift account.
16.UWCCC Breast Cancer Basic Research Fund, “Use of ß-Lapachone Analogs Against Human Breast Cancer”. P.I.: David A. Boothman, Ph.D. (0% salary). More than $50,000 in funds were raised primarily through the University of Wisconsin Comprehensive Cancer Center and the kind and generous efforts of Ms. Sara Hildebrand (Breast Cancer Inspiration Fund). Discretionary gift account, which was open for gift contributions to the lab’s research. May 1996-August 31, 1998.
17.National Institutes of Health (RO1), R01-CAEY67995-01, “Modulation of Retinoblastoma Control Proteins After X-Rays”, P.I.: David A. Boothman, Ph.D. (20% salary), $761,218 for 3 years, September 15, 1995-September 14, 1998.
18.Department of Energy, DE-FG02-93ER61707-06-09, "Role of Cell Cycle Regulation and the DNA Mismatch Repair Gene, hMLH1, in Adaptive Survival Responses", P.I.: David A. Boothman, Ph.D. (0% salary), $59,485 for 1 year, Dec. 1, 1997 to Nov. 30, 1998.
Confidential Page 17 4/8/2023
17
19.United States Army Breast Cancer Initiative, Post-doctoral Fellowship For Dr. John J. Pink (DAMD17-97-1-722), “Topoisomerase I-mediated Apoptosis in Breast Cancer” PI: David A. Boothman, Ph.D., Post-doctoral Fellow: John J. Pink, Ph.D., $120,000 for 3 years, July 1, 1997 - June 30, 2000.
20.Research Oncology Training Grant, CWRU, (PI: C. Distelhorst) Pre-doctoral fellowship, Student: Tracy Criswell, ~$20,000 for 1 year, started 07/01/00 to 06/30/01. Tracy was then able to secure her own extramural funding from the DOD.
21.Department of Defense (Breast Cancer Initiative, DAMD17-98-1-8260), “Cloning A Novel Apoptotic Protease Activated in Human Breast Cancer Cells After Poisoning Topoisomerase I”. PI: David A. Boothman, Ph.D. (20% salary), $100,000/yr for 3 years, September 15, 1998 - September 14, 2001.
22.Department of Energy (DE-FG02-99EQ62724)-09-12, Low Dose and Low Dose Rate Effects Initiative, “Nuclear apoJ: An X-ray-inducible cell death signal” P.I.: David A. Boothman, Ph.D., (30% salary), ~$1,120,000/yr total costs divided equally between Drs. Boothman and Aronow (U. Cincinatti). Scored 0.4%, top two grants in study section. Funded for 3 yrs, starting 11/01/98 to 10/31/01. Renewed below to Dr. Boothman alone.
23.Brain Tumor Society Awards, "Modulation of p53 for improved therapy of glioma" Post-doctoral Fellowship, Student: Arlene Hwang, salary + supplies, 2 years, 09/01/01-08/31/02.
24.Department of Defense (DOD, DAMD 17-00-1-0194), Breast Cancer Research Initiative, Pre-doctoral Fellowship, Student: Colleen Tagliarino, $60,000 for 3 years, started 04/01/00 to 03/31/03.
25.Department of Defense (DOD, DAMD 17-01-0194), Breast Cancer Research Initiative, Pre-doctoral Fellowship, Student: Mark Wagner, $60,000 for 3 years, started 04/01/00 to 03/31/03.
26.NIH/NCI/Ireland Comprehensive Cancer Center, Research Oncology Training Grant, Pre-doctoral Fellowship, Student: Kate Reinicke, stipend for two years, 07/01 through 06/30/03.
27. National Institutes of Health (1R01CA/ES78530-1), “Functions of xip8, an X-ray-inducible Ku70 binding protein”. P.I.: David A. Boothman, Ph.D., (20% salary), $231,238/yr, September 1, 1998 - August 31, 2003.
28. National Institutes of Health R01 (CA-83196-01), “Role of DNA mismatch repair in FdUrd-mediated cytotoxicity”. P.I.: David A. Boothman, Ph.D., (20% salary), ~$160,000/year, started 04/01/99 to 01/31/04.
29.Department of Defense, (DOD, DAMD-17-01-1-0196), Breast Cancer Research Initiative, Post-doctoral Fellowship, Student: Kostantin Leskov, Ph.D., $150,000 for 3 years, 07/01/01 to 06/31/04.
30.Department of Defense, (DOD, DAMD-01-1-0194), Breast Cancer Research Initiative, Pre-doctoral Fellowship, Student: Tracy Criswell, $64,240 for 3 years, started 07/01/01 to 06/31/04.
31.NIH/NCI R01, CA84578-02; P.I.: Kinsella, T.J.; “Mismatch repair defects and human tumor radiosensitization”. 01/25/00-12/31/03. The objective of this
Confidential Page 18 4/8/2023
18
grant are to exploit DNA MMR-deficiency for preferential radiosensitization by halogenated pyrimidine analogs; Overlap: None.
32.Department of Defense Prostate Cancer Initiative, (DOD, DAMD17-01-0038), "Exploiting NQO1, a radiation-inducible enzyme, using ß-lapachone for improved radiotherapy of prostate cancer”. $485,000 for 3 years, 04/01/01 to 03/31/04.
33.Department of Energy, DE-FG-022179-12-15; P.I. Boothman, D. A.; Clusterin: A Low Dose IR-Inducible Molecular Switch Between Life and Death, 10/01/01 - 05/31/05 $751,762; The objectives of this grant are entirely different from the NIH grant listed above. This grant focuses on the regulation of clusterin after low compared to high doses of IR, as well as to address the functions of nuclear compared to secretory forms of the protein; Budgetary overlap: None; Adjustments: None.
34.NCI/NIH R01 (CA92250-01), “Exploiting NQO1 for enhanced radiotherapy of breast cancer using ß-lapachone” PI: D. A. Boothman. $165.525 direct costs/yr, July 1, 2001 –June 30, 2005.
35.NIH/NCI P30, CA43703-12; P.I. Gerson, S.; Cancer Center Core Grant, CWRU and Univ. Hospitals; 08/01/01-07/31/06. Core grant for Ireland Comprehensive Cancer Center that supports facilities for cancer researchers. There is no direct support for research from this grant. Dr. Boothman is co-Leader of Experimental Therapeutics, Co-Director of BioNETT, Associate Director for Basic Research, and Co-Director of the Translational Research Core.
36.NIH/NCI R01, CA50595-10; P.I. Kinsella, T.J.; “Radiosensitization by halogenated nucleoside analogs”. 06/01/01-05/31/06. The aims are to test the efficacy of the IdUrd prodrug, IPdUrd; Overlap: None.
37.NIH/R01, (1 R01 CA102792-01), PI: Boothman, D.A., “Use of ß-lapachone for non-small cell lung cancer therapy”. 09/01/03-08/31/08. The aims of this grant are to exploit naturally elevated levels of the NQO1 enzyme specifically in non-small cell lung cancer (NSCLC) patients using newly developed NSCLC animal models, novel microsphere and nebulized drug delivery methods, and perform imaging of particles and drug, as well as examine preclinical antitumor efficacy of these novel drug delivery methods. Overlap: None.
38.Department of Defense (DoD) Idea Award, W81XWH-04-1-0164, Prostate Cancer Award Mechanism. PI: Boothman, David, A. $573,187 (total costs) for 3 years, 02/01/04-01/31/07. “Use of ß-lapachone-encapsulated millirods for improved therapy of prostate cancer.” The objectives of this grant are to develop low dose rate IR millirods for use in brachytherapy in combination with ß-lapachone, a novel apoptotic agent. Overlap: None with any grant.
39.DoD Pre-doctoral Award, W81XWH-04-1-0301, student: Melissa Bentle, 05/01/04-04/30/07. This student is expected to graduate 05/01/07. No overlap.
Confidential Page 19 4/8/2023
19
40.DoD Predoctoral Award, W81XWH-05-1-0248, student: Kathryn Reinicke/Amy Rommel, 04/01/05-03/31/09. Dr. Reinicke graduated 12/01/06. Ms Rommel assumed grant for one year. No overlap.
41.DoD Pre-doctoral Fellowship, W81XWH-05-1-0248 in Breast Cancer (Student: Amy Rommel) “Role of reactive free radicals in ß-lapachone-dependent cell death”, 03/01/2007-02/28/2008.
Present Support:41.Department of Energy (DOE) DE-FG02-06ER64186; PI: Boothman, DA.
102,000, 08/31/09-12/31/09 (No cost extension). IGF-1/IGF-1R-MAPK-secretory clusterin (sCLU) pathway: Mediator of a low-dose IR-Inducible bystander effect”. The objectives of this grant are to: (1) Determine the mechanisms by which p53 suppresses CLU promoter activity; (2) explore the role of sCLU in suppressing TGF-ß1 signal transduction; and (3) Determine the role of sCLU in bystander and adaptive survival responses with respect to IGF-1/IGF-1R/Src/MAPK/Erk-1/2/Egr-1.
42.Department of Energy (DOE), DE-FG-022179-18-21; P.I.: Boothman, D. A.; The IGF-1/IGF-1R-MAPK-Secretory Clusterin (sCLU) Pathway: Mediator of a Low Dose IR-Inducible Bystander Effect, 06/01/2009 – 05/31/2012, $1,425,000 total cost; The objectives of this grant are entirely different from the NIH grant listed above. This grant focuses on the regulation of clusterin after low compared to high doses of low LET or high LET IR, particularly to elucidate the role of TGF-ß1 to induce, and p53 to suppress, the insulin-like growth factor-1-secretory clusterin (IGF-1-sCLU) expression axis before and after IR, and to examine the roles of secretory clusterin in bystander and adaptive effects and as a marker of genetic instability; Budgetary overlap: None; Adjustments: None.
43.DoD Prostate Cancer Program Idea Award (W81XWH-06-1-0198), “Role of apoptosis inducing factor (AIF) in ß-lapachone-mediated cell death responses”. PI: David A. Boothman, Ph.D., $459,000 for 09/01/05 – 12/31/09.
44.DoD Pre-doctoral Fellowship (W81XWH-06-0748) In Breast Cancer. (Student PI: Eva Cataldo) “Mechanisms of IGF-1 induction after ionizing radiation (IR). $90,000 for 3 years, 09/01/2006-08/31/2009.
45.DoD Post-doctoral Fellowship (X81XWH-07-1-0078) in Prostate Cancer. (Student: Ying Dong, Ph.D.). “Use of ß-lapachone for the treatment of human prostate cancer cells”. 03/01/2007-02/28/2010.
46.DoD Post-doctoral Fellowship (X81XWH-09-1-0168) in Prostate Cancer. (Student: Xiuquan Luo, Ph.D.). “Role of senescent cells in radioresistant human cancer microenvironment”. 04/01/2009 – 03/31/2011.
47.NIH/R01, (1 R01 CA102792-01), PI: Boothman, D.A., “Use of ß-lapachone for non-small cell lung cancer therapy”. 05/01/03-08/31/13. The aims of this
Confidential Page 20 4/8/2023
20
grant are to exploit naturally elevated levels of the NQO1 enzyme specifically in non-small cell lung cancer (NSCLC) patients using nanoparticle (micelle)-delivered ß-lapachone. Pharmacokinetics of drug/micelle delivery, as well as pharmacodynamics of drug effectiveness are being explored. The biological component of this grant is exploring the mechanism by which ß-lapachone synergized with ionizing radiation, as well as explore the roles of b5R and P450R oxidoreductases in ß-lapachone toxicity to normal tissue. Overlap: None.
48.
Pending Support: 1. NCI/NHI, R01, “Role of Ku70 binding protein 5 (KUB5) in DNA repair and
genetic instability”. $250,000 direct costs per year, 12/01/2008-11/30/2013. Reviewed, received 1.8. Submitted.
2. NCI/NIH Challenge Grant, PI: Boothman, “Structure/function of human KUB5/Hera” $500,000/yr for 2 years. 09/01/2009-08/31/2011.
3. NCI/NIH GO Grant, “Genetic instability in cancer” PI: Gardner. Five (5%) percent effort.
Department of Energy, "Amplification of Cancer-associated Molecular Sites to Increase Binding of Radio-pharmaceuticals", Univ. of Alabama. P.I.: Donald Buchsbaum, Ph.D. X-ray-inducible markers will be utilized for radioimmunotherapy against head and neck cancers. 1995-1998.
Department of Energy, "Induced Genes and Proteins Following Radon Exposure In Mammalian Cells", Los Alamos National Laboratories, Los Alamos, NM. On this grant. X-ray-induced transcripts (xips) cloned by my laboratory will be examined for their induction by radon. 1993-1994.
Department of Energy, "Analyses of Radon-Inducible Proteins", Pacific Northwest Laboratories. This grant explores the analyses of radon-inducible proteins, specifically those my laboratory has previously described and are now isolating. 1994-1997.
External Advisory Board, Johns Hopkins University Comprehensive Cancer Center, Baltimore, MD., 1997-2000.
External Advisory Board, P41 RARAF Microbeam Facility Resources Grant, College of Physicians and Surgeons of Columbia University, Department of Radiation Oncology, Center for Radiological Research, New York, NY 10032. PI: David Brenner. 1998-Present
Internal Advisory Board Member and Chair, UTSouthwestern NSCOR (Dr. J. Minna, PI), May, 2007-Present.
External Advisory Board, Glioma Program Project Grant, NSCOR Application, Space Radiation Effects on CNS Tissue Microenvironment and Glial Cell Function, UTSouthwestern and University of Rochester, M.
Confidential Page 21 4/8/2023
21
Kerry O'Banion, MD, PhD Director, Medical Scientist Training (MD-PhD) Program Associate Professor of Neurobiology & Anatomy, University of Rochester. 2009-Present.
PARTICIPATION IN CLINICAL TRIALS (Phase I /UO1)Co-Principal Investigator, Approved Phase I protocol entitled, "Phase I Study of
Topotecan and Thoracic Radiation" (CO 9492), Jan. 1, 1995-1996, U. Wisc. (published, see below).
Co-Investigator, Approved Phase I protocol entitled, “Phase I Clinical Trial of Rebeccamycin Tartrate” (CO 9493), U. Wisc.. Sept. 1, 1995-1998.
Co-investigator, Phase I Protocol, “Phase I Clinical Trial Using Flavopyridol” (CO 9495) against head and neck cancers. U. Wisc., Oct. 1996-2000.
Co-investigator, Phase I protocol entitled, “Phase I Trials of Oral 9-aminocamptothecin (NSC-603071) and IR, U. Wisc., September, 1996-2000.
PATENTS1. “Synthesis and use of ß-lapachone analogues”: Patent #:
US5763625. David A. Boothman, Benjamin Frydman, and Donald T. Witiak (deceased). Patent awarded 01/01/98 through Wisconsin Alumni Research Foundation (WARF). Currently licensed to S’lil Corporation, Madison, WI.
2. “Lapachone delivery systems, ser #60/374,693, filing date: April 23, 2003, Case Western Reserve University (CWRU).
3. “Lapachone delivery systems, compositions and uses related thereto”. Serial #: 10/422,058, April 23, 2003, CWRU.
4. “A monoclonal antibody to a novel Ku70 binding protein, KUB5” disclosed, September, 2003, CWRU.
5. “Use of the testosterone-repressed prostate message-2 (TRPM-2) for improved radio- genetherapy”. September, 2003, CWRU.
6. “A simple ELISA technique for evaluating secretory clusterin protein levels in blood and tissues”. CWRU, September, 2003.
HONORS AND AWARDSWayne State University Sciences and Humanities Symposium Award, Sponsor:
National Science Foundation, Detroit, MI, 1975.National Science Foundation Secondary Science Training Program Scholarship,
Sponsor: National Science Foundation, Tallahassee, FL, 1975.American Association for Cancer Research Upjohn Travel Award, Houston,
Texas, 1985.Listed in "Marquis Who's Who In Science & Engineering In America",1992-PresentNominated by Dept. Human Oncology for Gertrude Elion Award, AACR, 1995Nominated by Dept. Human Oncology for Kimmel Scholar Award, 1996Nominated by Dept. Human Oncology for Romnes Scholarship, 19961999 Radiation Research Travel Award, Dublin, Ireland, July 18-23, 1999
Confidential Page 22 4/8/2023
22
Student Awards (Awards received by students while in my laboratory):
ASTRO Fellowship (Student: Nina Fukunaga, M.D.) 1990Radium Society Travel Award (Student: Nina Fukunaga, M.D.) 1991ASTRO Fellowship (Student: Randi A. Schea, M.D.) 1991ASTRO Fellowship (Student: Walter Sahijdak, M.D.) 1992ASCO Fellowship (Student: Nina Fukunaga, M.D.) 1992Radiological Soc. North America (Student: Nina Fukunaga, M.D.) 1992American Association for Cancer Research (AACR) Upjohn
Travel Award (Student: Janet Owens) 1992Eli Lily Travel Award (Student: Janet Owens) 1992Radiation Research Travel Award (Student: Randi Schea, M.D.) 1992Pardee Foundation Post-doctoral Fellowship (Ike Lee, Ph.D.) 1992Pre-doc Cancer Biol. Training Fellowship (Student: Janet Owens) 1992ACS Clinical Oncology Career Development Award (Student:
Nina Fukunaga, M.D.) 1993Radiation Res. Society Student Travel Award (Student: Mark Meyers) 1994AACR Upjohn Travel Award (Student: Mark Meyers) 1994ASTRO Fellowship (Student: John P. Lamond, M.D.) 1994RSNA Fellowship (Student: John P. Lamond, M.D.) 1994Radiation Research Travel Award (Student: John P. Lamond, M.D.) 1995Radiation Research Travel Award (Student: Chin-Rang Yang) 1995International Radiation Research Award For Wurzberg,
Germany (Student: Chin-Rang Yang) 19951996 Hoffmann-La Roche Travel Award, 84th Ann. Amer. Assoc, For
Cancer Research Meeting, Wash., D.C. (Student: Chin-Rang Yang) 19961996 UW Trewartha Grant For Honors Thesis (Student: Lyssa Bierig) 19961996 U.S. Army Breast Cancer Fellowship (Student: Dr. John Pink) 1996AACR Hoffman La Rouche Travel Award (Student: Mark Meyers) 1997RSNA Fellowship (Student: Ann Czyzewski-Dunphy, M.D.) 1997Susan Komen Travel Award (Student: John J. Pink, Ph.D.) 1997MD Anderson Research Conference Award, “Molecular Targets for
Cancer Therapy and Prevention” (Student: C-Y. Yang, Ph.D.) 1999Radiation Research Society Student Travel Award, 47th Annual Meeting
of the Radiation Research Society, Albequerque, NM (Student: Konstantin "Kostya" Leskov) 2000
Radiation Research Society Marie Curie Travel Award Finalist(Student: Konstantin Leskov) 2000
Research Oncology Training Grant Fellowship Award (Student: Colleen Tagliarino). 2000
Department of Defense, Breast Cancer Initiative Pre-doctoral Fellowship(Student: Colleen Tagliarino) 2000
Department of Energy. Student, Tracy Criswell (Dept. Pathology), selected as the CWRU choice for attendance to the 50th Anniversary meeting of Nobel Laureates in Landau, Germany. Ms Criswell was then selected to attend the meeting by the Dept. of Energy as one of 30 students selected from a pool of >200 nominations from Univer-
Confidential Page 23 4/8/2023
23
sities and National Labs in the United States. 2000Dean's Award for Excellence in Undergraduate Teaching By A Graduate
Student. (Student: Colleen Tagliarino) 2000Research Oncology Training Grant Pre-doctoral Fellowship (Student:
Tracy Criswell) 2000Gordon Research Conference Travel Award (Student: Tracy Criswell),
Radiation Oncology 2001Vilas Travel Award for 2001, (Student: Kostya Leskov, Human Oncology,
UW) University Wisconsin-Madison Graduate School 2001DOD Pre-doctoral Fellowship (Student: Tracy Criswell) 2001-2003DOD Post-doctoral Fellowship (Student: Kostantin Leskov, Ph.D.) 2001-2003Research Oncology Training Grant Pre-doctoral Fellowship (Student:
Kathryn Reinicke, Biochemistry) 2001-2003Graduate Student of the Year Award, Dept. of Pharmacology, (Student:
selected as the CWRU choice for attendance to the 53trd Anniversary meeting of Nobel Laureates in Landau, Germany. Ms Reinicke was then selected to attend the meeting by the Dept. of Energy as one of 30 students selected from a pool of >200 nominations from Universities and National Labs in the United States. 2003
Graduate Student Travel Award, (Student: Tracy Criswell), Annual Radiation Research Society Meeting. April, 2003
Department of Energy. Student, Melissa Bentle (Dept. Pharmacology), selected as the CWRU choice for attendance to the 54th Anniversary meeting of Nobel Laureates in Landau, Germany. Ms Bentle was then selected to attend the meeting by the Dept. of Energy as one of 30 students selected from a pool of >200 nominations from Universities and National Labs in the United States. Melissa was the third student to bechosen to attend this Nobel Laureates meeting. 2004
Aging and Cancer Post-doctoral Fellowship, Arlene Hwang, Ph.D. 2003-2004Aging and Cancer Post-doctoral Fellowship, Erik A. Bey, Ph.D. 2004Graduate Student of the Year, department of Pharmacology, (Student:
Melissa Bentle) 2004DOD Breast Cancer Pre-doctoral Fellowship (Student: Melissa Bentle)
2005-2007DOD Breast Cancer Pre-doctoral Fellowship (Student: Kathrynn
Reinicke) 2005-2007DOD Breast Cancer Pre-doctoral Fellowship (Student: Eva
Cataldo) 2007-2009DoD Breast Cancer Pre-doctoral Fellowship (Student: Amy Rommel) 2007-2008
Confidential Page 24 4/8/2023
24
DoD Prostate Cancer Post-doctoral Fellowship (Student: Ying Dong,PhD) 2008-2011
Cancer Biology Training Grant Post-doctoral Fellowship (Student:Julio Morales, PhD) 2008-2010
DoD Prostate Cancer Post-doctoral fellowship (Student: XiuquanLuo, PhD) 2009-2011
MEMBERSHIPS AND OFFICES HELD IN PROFESSIONAL SOCIETIES
Memberships Since:.American Society for Microbiology 1983Sigma Xi 1985American Association for Cancer Research 1987Radiation Research Society 1987American Association for the Advancement of Science 1989International Atomic Energy Agency (IAEA) 1992
Offices Held.Director, Eastern Student Research Forum, Sponsor:
AMA, Miami, FL 1985-1986
PROFESSIONAL ACTIVITIES/SERVICEUniversity and State:At The University of Wisconsin-Madison:
Human Oncology Graduate Steering Committee 1993-1998Search Committee for Medical Oncology Faculty 1993-1994Environmental Toxicology, Health Related Toxicology Committee 1993-1996DHO Administrative Advisory Committee 1994-1998Shared Resources Subcommittee, Integrated Health Sciences Planning Committee 1993-1998UWCCC Presenter for Board of Donors 1993-1998Search and Screen Committee, Breast Cancer Program, Department of Human Oncology 1994-1995Environmental Toxicology Admissions Committee 1993-1996Member, joint biweekly lab meetings (w/Drs. Clark, Moser & Miyamot) 1993-1996Chair, Department of Human Oncology Colloquium Series Fall, 1994UW-Madison Medical School/M.D., Ph.D. Liaison Committee Member 1994-1997Co-organizer, DNA Repair and Genomic Instability Meetings 1994-1997Mentor, The Mentor Program, 104 South Hall; Benjamin
H. Rodriguez, Assistant Dean, Mentor Program Director 1994-1998Advisory Committee for the Undergraduate Program in
Cellular and Molecular Biology 1994-1998Laboratory Advisory Committee, DHO 1994-1998UW-Madison Medical School Admissions Committee 1994-1998Member, Human Gene Therapy Center, Waisman Center,
University of Wisconsin 1995-1998
Confidential Page 25 4/8/2023
25
DHO Capital Exercise Committee 1995-1998UWCCC /Dept. Human Oncology Faculty Safety Advisor 1996-1998Trainer, Department of Pharmacology Training Grant 1997-1998Trainer, Inst. of Aging Training Grant (R. Weindruch, Coordinator) 1996-1998DHO representative, Faculty Senate 1997-1998DHO Basic Science Chair’s Meeting (substitute for
Dr. Mehta, Chair, DHO) 1997-1998Grant Reviewer for Sigma Delta Epsilon, Graduate Women in Science, Inc.
(The Eloise Gerry Fellowship Fund) 1998-2000
At CWRU:Co-Leader, Developmental Therapeutics, Case Comprehensive
Cancer Center, CWRU 1998-2005Departmental Review Committee (Radiation Oncology, CWRU 1999-2005Steering Committee, Research Oncology Training Grant 1998-2005Steering Committee, Pharmacology, Training Grant 1998-1999Committee on Appointments, Promotions, and Tenure, Department
Of Radiation Oncology (Helen Evans, Ph.D., Chair) 1999-2005Recombinant DNA Safety Committee (David Samols, Chair) 1999-2003Breast Cancer Physician Scientist Search Committee
(C. Distelhorst, Chair) 1999-2001Co-Leader, Case Comprehensive Cancer Center, Breast Cancer
Research Working Group 1999-2001Member, Case Comprehensive Cancer Center Prostate Cancer
Working Group 1999-2001Member, Case Comprehensive Cancer Center, Flow Cytometry
Advisory Committee 1999-2005Co-organizer, Case Comprehensive Cancer Center Fall Retreat 06/1999Facilities Reviewer, Case Comprehensive Cancer Center,
“Radiation Resources”, 1999-2005Athymic Animal Core Facilities Reviewer, 1999-2005Session Leader, Department of Pharmacology Fall Retreat 1999Grant Reviewer for ACS Pilot Grants, Case Comprehensive Cancer
Center, ACS New Investigator Pilot Grants 1999-2005Micro-array Core Facility Advisory Committee, Case Comprehensive
Cancer Center 1999-2005CME Accreditation Committee (Chair: A. Dowlatti, M.D.) 2000-2005Radiation Safety Committee, DOES 2000-2003Histology Core Facility Advisory Committee, Case Comprehensive
Cancer Center 2000-2005Grant Reviewer, Presidential Technology Development
Fund (PTDF), CWRU 2001-2005Co-Leader, Translational Research Core 2002-2005Co-Leader, BioNETT (Awarded $5,000,000 by Presidental
Research Excellence Award 2003-2005Chairman, Case Comprehensive Recruitment Committee 2004-2005Coordinator, Case Cancer Center Working Group in Apoptosis 2004-2005
Confidential Page 26 4/8/2023
26
Coordinator, Case Cancer Center Working Group in TGF-ß1 Signaling 2004-2005
At University of Texas Southwestern Medical Center at Dallas:Co-Director, DNA Damage and Repair Program, Simmons
Cancer Center 2005-PresentCo-Leader, Cancer Biology Training Grant 2005-PresentAssociate Director for Translational Research, Simmons
Comprehensive Cancer Center, UTSW 2005-Present
Community Service (dates in bold indicate permanent service) :Discuss Cancer and Cancer Research with 3rd and 4th Graders, “The Lunch
Bunch”, Glenn Stevens Elementary School, Rosa Road, Ms. Anne Meiham, Coordinator, Rose Elementary School, Madison, WI 1996-1998
25th Anniversary of UWCCC, Cancer Therapy and Radiation OncologyPresentation, August 25, 1997
American Cancer Society Walk for Cancer Cure Gave Presentationsfor Cancer Center and ACS Donors February, 1998
Verona Grade/Middle/High School, The Best and the Brightest ProgramMentored Students: Matt Glass, 7th Grader; March, 1998
Discuss Cancer Research With Senator Sherrod Brown, Ohio February, 1999Discussed Cancer Research with Reporter Delphia Ricks, March, 1999Cancer “Angles” Program, Nonprofit Cancer Support Group: DiscussCancer Research with women's groups and cancer survivors Jan., 2000-2005Participate in Minorities Undergraduate Summer Research
Studies May 2000-2005Participated in "Catalyst Program", Gilmore Academy High School Sept., 2000-2005
National/International Seervice (dates in bold indicate permanent/current service) :Department of Energy (DOE), ad-hoc peer-review for
DOE grant applications in Health Effects Biological Sciences Division. (Marvin Frazier, Monitor) 1990-2000
Co-Organizer and Program Committee, Radiation Res. Mini-symposium on Inducible Repair, Vancouver, CD 1993-1994
United States Army Medical Research and Development Command, reviewer for AIBS proposals on Breast Cancer , panel, Molecular Biology 4B, 1994
Co-organizer and Program Committee, "Gene Induction and Adaptive Responses in Irradiated Cells: Mechanismsand Clinical Implications, Montreal, Canada, 1993-1994
Grant Reviewer, The Israel Science Foundation, (Prof.Israel Pecht, Director) May, 1994
Grant Reviewer, American Health Foundation, Valhalla, New York (Stephen S. Hecht, Ph.D., Director) May, 1994
Confidential Page 27 4/8/2023
27
Program Committee, Radiation Research Society Annual Meeting, San Jose, California, March 31-April 5, 1995 1994-1995
Member, Abstract Sorting Committee, Radiation Research Society Annual Meeting, Chicago, Il 1994-1995
NCI Program Project Site Review, Stanford University, CA(Rod Withers, Chair, F. Fabar, Organizer) Sept. 18-20,1994
Grant Reviewer, Medical Research Council of Canada, Ottawa, Canada (Ghislaine Bradley, MRC Coordinator) 1994
DOE Program Site Visit, University of California San Francisco,San Francisco, CA March, 1995
Editor, RAPHEX Exam, Advanced Medical Publishing, Madison, WI 1995-1998
Scientific Review Administrator), June 5-8, 1996 June, 1996Grant Reviewer, NIH Site Visit, Exp. Therapeutics #2 Study Section
June, 1996Grant Reviewer, Experimental Therapeutics #1 Study Section August, 1996Editorial Board, Radiation Research (Associate Editor) 1996-1998Ad hoc Reviewer, NCI Radiation Biology Study Section ad hoc member, October review period. 1996-1999Grant Reviewer, AIBS US Army Breast Cancer Research Initiative,
ad hoc reviewer, Periodic teleconference reviews. 1993-1995Tenure Review, Institute of Biomedical Research, Taiwan Sinica University,
(Kenneth Wu, Chairman), Periodic reviews. 1998-2001Grant Reviewer, DOE Study Sections, “Low Dose and Low
Dose Rate Effects”, May review period. 1998-PresentGrant Reviewer, DOD, US Army Breast Cancer Initiative 1998-Present (Yearly)Grant Reviewer, DOD US Army Prostate Cancer Initiative 1995-Present (Yearly)Grant Reviewer, DoD Concept Awards for Breast Cancer 1999-Present (Yearly)Grant Reviewer, DOD, US Army Ovarian Cancer Initiative Feb. 1999-2003Grant Reviewer, NIH, Program Project Grant on DNA Repair January, 1999Grant Reviewer, NIH (NCI) Special Radiation Research
Study Section Oct 13, 1999Grant Reviewer, NIH Review of Iowa Comprehensive Cancer Center
(Dr. Gail Bryant, SRA, NIH) January, 2000Grant Reviewer, NIH Parent Committee ad-hoc member to discuss
Review of Iowa Comprehensive Cancer Center Application April 10, 2000Grant Reviewer, NIH New Insights into Breast Cancer
Research Program. April, 2000Grant Reviewer, ad hoc NIH Experimental Therapeutics II
Study Section Feb.-June, 2000Grant Reviewer, Permanent member, NIH Experimental
Therapeutics II (ET-2) Study Section October, 2000-June, 2003Grant Reviewer, Alberta Cancer Board, Dec., 2000Grant Reviewer, Scottish Hospital Endowments Research Trust May, 2001
Grant Reviewer, Scottish Hospital Endowment Research Trust (SHERT) sponsored by The Biomedical & Therapeutic Research Committee (BTRC) of the Chief Scientist Office in Edinburgh, Scotland 2001-Present
Grant Reviewer, NIH/NCI, "Head and Neck Cancer SPOREs" March, 2002Grant Reviewer, NIH Special Emphasis Panel July, 2003Grant Reviewer, Permanent member, NIH Developmental Therapeutics (DT)
Study Section October, 2001-2006Grant Reviewer, NCI/NIH Head and Neck SPOREs March, 2003Chairman, Special Emphasis Panel Review
(SRA: Dr. Mary Bell) August, 2003Chairman, Special Emphasis Panel Review (SRA: Dr.
Mary Bell) November, 2003Grant Reviewer, Canadian Cancer Institute, PPG,
Toronto, CA December, 2003Grant Reviewer, Apoptosis Focused Program Project
Grant Special Emphasis Panel October, 2004Grant Reviewer, NIH/NCI Breast Cancer SPOREs February, 2005Grant Reviewer, F09 Fellowship Applications February, 2004-July, 2006Grant Reviewer, NIH/NCI DMP Study Section October 5-6, 2006Grant Reviewer, Komen Breast Cancer Research
Foundation, Develop. Therapeutics Study Section Dec, 2007-Jan., 2009Grant Reviewer, State of Pennsylvania Cancer Research Program (3X/year) December, 2005-PresentGrant Reviewer, State of California Breast Cancer Research Program March, 2007-PresentGrant Reviewer, NCI/NIH SPORE applications, Special Emphasis Panel (Manzoor Zarger, SRA) September, 2008Grant Reviewer, NIH/NCI, DT Study section (SRO: Sharon Gubanovich, Ph.D.) January, 2009Grant Reviewer, NIH/NCI, Special Emphasis Panel P01 Review (Manzoor Zarger, SRA) February, 2009Grant Reviewer, NIH/NCI, ARRA Challenge Grants (Cathleen Cooper, SRA) June, 2009Grant Reviewer, NIH/NCI, SBIR/STTR Grants (Eun Ah Cho, Ph.D., SRA) July, 2009Grant Reviewer, NIH/NCI Grand Opportunities ARRA Grants (Adriana Stoica, SRO) August, 2009
Grant Reviewer, NHI/NCI P01 Special Emphasis Panel Review (Manzoor Zarger, SRO) September, 2009Grant Reviewer, DoD Lung Cancer Concept Awards
LCRP CET, LCRP CET-CAM, and LCRP END/IMM/PBYStudy sections October, 2009
Grant Reviewer, Komen Breast Cancer Research Foundation, Develop. Therap. Study Section (3 year commitment) Nov., 2009-present
Confidential Page 29 4/8/2023
29
Grant Reviewer, NIH Integrated in Biology Study Section(Adriana Stoica, SRO) November, 2009
Grant Reviewer, The Johns Hopkins University FAMRI Center of Excellence (http://www.hopkins-famri.org/ <http://www.hopkins-famri.org/> ), Flight Attendants Medical Research Institute, (Margaret Chamberlin, AIBS, SRO) December, 2009
Grant Reviewer, NHI/NCI P01 Special Emphasis Panel Review (Manzoor Zarger, SRO) January, 2010
MAJOR RESEARCH INTERESTS
1. Cellular and molecular biology of DNA repair and damage-inducible responses in mammalian cells.
2. Cellular and molecular biology of eukaryotic gene expression and the role(s) of X-ray-inducible genes in cell cycle regulation and apoptosis.
3. Development of novel delivery methodology, including nanoparticle micelles, cRGD-containing nanoparticles, and millirods.
4. Role of DNA mismatch repair, specifically MLH1, in G2/M cell cycle control and apoptosis.
6. Changes in gene expression during aging and the involvement of failing DNA repair processes in aging.
7. Cellular and molecular biology of cell cycle checkpoint responses.
TEACHING ACTIVITIESFormal Teaching:
Courses Taught:As Undergraduate/Graduate Student
Taught transmission electron microscopy, University of Michigan, Ann Arbor, Instructor: Dr. Dusan Biac, 27 hrs/semester 1979-1981
Teaching Assistant, Microbiology and Immunology undergraduateand medical laboratories, Univ. of Miami, Florida, 30 hrs/sem. 1982-1985
Lectured in graduate courses in Virology and Microbial Genetics, University of Miami, Miami, Florida, 1984-1985
At Univ. Michigan, Asst. ProfessorLectured on DNA Repair, Chromosomal Alterations,
Human Genetics 542, Univ. Michigan, 2 hrs/semester Fall, 1991Lectured in the Radiobiology course, Dept. Radiation Oncology,
University of Michigan on "DNA Repair, Chemotherapy,and Radiation Effects on Embryo & Fetus", 8 hrs/semester. 1990-1992
At Univ. Wisconsin, Asst. Professor/Assoc. ProfessorLectured and Co-organized, Human Oncology, DHO 621,
Organized and Taught course, entitled “DNA Repair” (HO 480-755), 5 hrs/wk. x 14 weeks, Course is taught in Fall semesters, odd years.(course evaluations available from the Department of Human Oncology) 1995-1998
At CWRU as Assoc. Professor,/Professor:Organize and Teach course, EVHS502: “DNA Damage
and Repair”, (2X/wk, 3h/session), Co-organizer, Dr. David Sedwick, Env Hlth Scis. (taught every other year,Last taught Fall, 2001 Spring, 1999-2005
Lectured on “DNA Repair” (two 3 h seminars), In: BIOC420: Cellular and Molecular Biology Of Cancer, Instructor: Dr. Ed Stavnezer, Biochemistry Fall, 1999-2005
Lectured on “DNA Repair Mechanisms and Drug Resistance”,(one, 3h seminar) PHRM 434 (or MVIR 4343 or MBIO 434):Mechanisms of Drug Resistance Spring 2000-2005
Lectured on "Radiation Damage and Carcinogenesis" as partof 'Introduction to cancer biology' (PHRM 541, 2X 1.5h) (Instructor: Dr. David Danielpour) Sept., 2001-2005
At UTSW as Professor:Organizer, Cancer Biology Dinner Meetings Sept. 2008-PresentLectured on “DNA Damage and Repair” as part of the “Introduction
To Cancer Biology”, Cancer Biology Training Grant Dec., 2005-Present
b. Training Programs:-At University of Michigan:
Interdisciplinary Studies of Cancer Biology, University of Michigan, Cancer Biology Training Grant (Institutional National Research Service Award), NIH, NCI. Sept., 1991-June, 1993
-At University of Wisconsin:Human Oncology Cancer Biology Training Grant,
University of Wisconsin, Madison, WI. 1993-1998Environmental Toxicology Training Grant 1993-1998Molecular and Cellular Biology Training Grant 1993-1998Cellular and Molecular Pharmacology Training Grant 1996-1998Institute on Aging Training Grant 1997-1998
-At Case Western Reserve University:Visiting Professor, Department of Human Oncology, UW and Trainer,
Confidential Page 31 4/8/2023
31
Human Cancer Biology Program, UW 1998-2008Trainer, Clinical Oncology Training Grant, CWRU 1998-2005Trainer, Research Oncology Training Grant, CWRU 1998-2005Trainer, Cellular and Molecular Basis of Disease, Department of
Pathology, CWRU 1998-2005Trainer, Environmental Health Sciences Program, CWRU 2000-2005
-At UTSW:Trainer, Cancer Biology Training Program 2005-PresentTrainer, Genes and Development 2005-PresentTrainer, Pharmacology 2005-PresentTrainer, Genetics 2006-Present
Supervisory Teaching:
b1. Advisory Committees: -At Univ. of Wisconsin-Madison:
Shabana Insaf Ph.D. Pharmacy Graduated, 1995Kris Sachsenmeir Ph.D. Environ. Tox. Graduated, 1996Mei-Ling Kuo Ph.D. Human Oncology Graduated, 1997Shu-yaun Yeh Ph.D. Endocrinology Graduated, 1997Jill de Jong Ph.D. Human Oncology Graduated, 1997Eric Chen Ph.D. Human Oncology Graduated, 1997Peter Reddig Ph.D. Dept. Human Onc. Graduated, 1998Helen Moinova Ph.D. Human Oncology Graduated, 1998Angie Wild Ph.D. Human Oncology Graduated, 1999John J. Pink Ph.D. Human Oncology Graduated, 1999
Ph.D. Human Oncology Graduated, 1999Konstantin Leskov Ph.D. Human Oncology Graduated, 2001Shelly Wuerzberger-Davis Ph.D. Human Oncology Graduated, 2004*Has achieved dissertator status.
-At Case Western Reserve University:
Jerry Chipuk (Danielpour) Ph.D. Pharmacology Graduated, 2002Steven Zieleske (Gerson) Ph.D. Hemat/Oncol. Graduated, 2002 Kedar Hastan (Muhktar) Ph.D. Dermatology Graduated, 2003Nicole Bianco Ph.D. Pharmacology Graduated, 2003Arun Rainin Ph,D, Pathology Graduated, 2004Michael Mann Ph.D. Genetics Graduated, 2004Yidou Hang Ph.D. Genetics Graduated, 2005Fangjing Wang Ph.D. Biomed. Engin. Graduated, 2006Caren Lee Ph.D. Biomed. Engin. Graduated, 2006Saejang Kim Ph.D. Biomed. Engin. Graduated, 2006
-At UT Southwestern Medical Center at Dallas:Oliver Delgado Ph.D. Genes and Dev. 2005-Present
Eva Cataldo Ph.D. Pharmacology Graduated, May, 2009Amy Rommel Ph.D. Cancer Biology 02/06 - Present
b3. Postgraduates Supervised:
-At University of Michigan-Ann Arbor:Ike W. Lee Ph.D. Radiation Oncology 07/92-06/93
-At University of Wisconsin-Madison:Thomas W. Davis Ph.D. Human Oncology 01/94-07/98John J. Pink Ph.D. Human Oncology 12/95-08/98
-At Case Western Reserve University:John J. Pink Ph.D. Radiation Oncology 09/98-05/02Chin-Rang Yang Ph.D. Radiation Oncology 09/98-09/99Han Li Ph.D. Radiation Oncology 09/99-12/00Jing Li Ph.D. Radiation Oncology 10/00-04/03
-At UTSW:Jonathon Herpers High School Student 05/08 - 09/09Stephanie Fishman High School Student 05/08 - 09/08Samantha Lau Undergraduate 04/09 - 09/09Malina Patel High School/STARS 09/09-Present
1Minority Student Summer Research Program (Medical School, Gloria Hawkins, Director).2Professional Experience Program, Biology Department, UW-Stevens Point, Kent D. Hall, Dir.)3Special students, Madison Metro School District Research Program (T. Milhon, Director).4Special summer research student (M. Sussman, director).5Work-study interns; 6Undergraduate Honors Thesis.
BIBLIOGRAPHY
Publications In Scientific Journals.
a. Peer-Reviewed Articles.
(Papers 1-6 were published from Dr. Boothman’s doctoral work at U. Miami, S. Greer, Ph.D., advisor)
1. Mekras, JA, Boothman, DA, Perez, LM, and Greer, S. Use of 5- fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapy. 1984; Cancer Research 44: 2551-2560.
2 Boothman, DA, Briggle, TV, and Greer, S. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture. 1985; Molecular Pharmacology 27: 584-594.
3. Mekras, JA, Boothman, DA, and Greer, S. Use of trifluoromethyl-deoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. 1985; Cancer Research 45: 5270-5280.
4. Briggle, TV, Boothman, DA, Pfaffenberger, CA, and Greer, S. Analysis of 5-fluoro-2'-deoxycytidine and 5-trifluoromethyl-2'-deoxycytidine and their related antimetabolites by high performance liquid chromatography. 1986; J. Chromatography 381: 343-356.
5. Boothman, DA, Briggle, TV, and Greer, S. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755. 1987; Cancer Research 47: 2344-2353.
6. Boothman, DA, Briggle, TV, and Greer, S. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. 1987; Cancer Research 47: 2354-2362.
(Papers 7-11 were published during Dr. Boothman’s post-doctoral work at Harvard, A. B. Pardee, Ph.D., advisor)
Confidential Page 36 4/8/2023
36
7. Boothman, DA, Greer, S, and Pardee, AB. Potentiation of halogenated pyrimidine radiosensitizers by ß-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. 1987; Cancer Research 47: 5361-5366.
8. Boothman, DA, Schlegel, R, and Pardee, AB. Anticarcinogenic potential of DNA-repair inhibitors. 1988; Mutation Research 202: 393-411.
9. Boothman, DA, Trask, DK, and Pardee, AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by ß-lapachone, an activator of topoisomerase I. 1989; Cancer Research 49: 605-612.
10. Boothman, DA, and Pardee, AB. Inhibition of radiation-induced neoplastic transformation by ß-lapachone. 1989; Proc. Natl. Acad. Sci., USA 86: 4963-4967.
11. Boothman, DA, Geller, AI, and Pardee, AB. Expression of the E. coli Lac Z gene from a defective HSV-1 vector in various human normal, cancer-prone and tumor cells. 1989; FEBS Letters 258: 159-162.
(Papers 12-19 were published from work at U. Michigan, A.S. Lichter, M.D., Chair)
12. Boothman, DA, Bouvard, I, and Hughes, EN. Identification and characterization of X-ray-induced proteins in human cells. 1989; Cancer Research 49: 2871-2878.
13. Santos, O, Perez, LM, Briggle, TV, Boothman, DA, and Greer, S. Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine. 1990; Int. J. Radiat. Oncol. Biol. Phys. 19: 357-365.
14. Hughes, EN, and Boothman, DA. Effect of caffeine on the expression of a major X-ray-induced protein in human tumor cells. 1991; Radiation Research 125: 313-317.
15. Boothman, DA, Wang, M, and Lee, SW. Induction of tissue-type plasminogen activator by ionizing radiation in human malignant melanoma cells. 1991; Cancer Research 51: 5587-5595.
16. Boothman, DA, and Lee, SW. Regulation of gene expression in mammalian cells following ionizing radiation. 1992; Yokohama Medical Bulletin 42:137-149.
17. Boothman, DA, Wang, M, Schea, RA, Burrows, HL, Strickfaden, S, and Owens, JK. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. 1992; Int. J. Radiat. Oncol. Biol. Phys 24: 939-948.
18. Fukunaga, N, Schea, RA, Burrows, HL, and Boothman, DA. Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. 1992; Int. J. Radiat. Oncol. Biol. Phys. 24: 949-957.
19. Boothman, DA, Meyers, M, Fukunaga, N, and Lee, SW. Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells. 1993; Proc. Natl. Acad. Sci., USA 90 (15): 7200-7204.
(Papers 20-39 were published from work at the U. Wisconsin-Madison, T.J. Kinsella, M.D., Chair)
Confidential Page 37 4/8/2023
37
20. Boothman, DA, Majmudar, G, and Johnson, T. Immediate X-ray-inducible responses from mammalian cells. 1994; Radiation Research 138: 44-46.
21. Boothman, DA. Enhanced malignant transformation is accompanied by increased survival recovery following ionizing radiation in Chinese hamster embryo fibroblast cells. 1994; Radiation Research 138: 121-125.
22. Sahijdak, WS, Yang, CR, Zuckerman, JS, Meyers, M, and Boothman, DA. Alterations in transcription factor binding in radioresistant human melanoma cells following ionizing radiation. 1994; Radiation Research 138: 47-51.
23. Boothman, DA, Lee, IW, and Sahijdak, WS. Isolation of an X-Ray-Responsive Element (XRE) in the promoter region of tissue-type plasminogen activator: potential uses of XREs for gene therapy?" 1994; Radiation Research 138: 68-71.
24. Boothman, DA, Fukunaga, N, and Wang, M. Down-regulation of topoisomerase I following ionizing radiation in mammalian cells. 1994; Cancer Research 54: 4618-4626.
25. Boothman, DA, Davis, TW, and Sahijdak, WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. 1994; Int. J. Rad. Oncol. Biol. Phys. 30(2): 391-398.
26. Planchon, S, Wuerzberger, S, Frydman, B, Witiak, DT, Hutson, P, Church, D, Wilding, G, and Boothman, DA. ß-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. 1995; Cancer Research 55: 3706-3711.
27. Lamond, JP, Mehta, MP, and Boothman, DA. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: review of the synergistic effect between topotecan and radiation. 1996; J. Neuro-Oncology 30(1): 1-6.
28. Lamond, JP, Kinsella, TJ, Wang, M, and Boothman, DA. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. 1996; Int. J. Radiat. Oncol. Biol. Phys. 36(2): 361-368.
29. Lamond, JP, Kinsella, TJ, Wang, M, and Boothman, DA. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. 1996; Int. J. Radiat. Oncol. Biol. Phys. 36(2): 369-376.
30. Boothman, DA, Meyers, M, Odegaard, E, and Wang, M. Altered G1
checkpoint control determines adaptive survival responses to ionizing radiation. 1996; Mutation Research 358(2): 143-153.
31. Meyers, M, Davis, TW, Van Patten, C, Odegaard, E, Fishel, R, and Boothman, DA. Cell cycle regulation of the human DNA mismatch repair genes, hMSH-2, hMLH-1 and hPMS-2. 1997; Cancer Research 57(2): 206-208.
32. Glen, VL, Hutson, PR, Kehrli, NJ, Boothman, DA, and Wilding, G. Reversed-phase high-performance liquid chromatography method for determination of beta-lapachone and 3-hydroxy-beta-lapachone in plasma. 1997; J. Chromatography 692 (2): 181-186.
Confidential Page 38 4/8/2023
38
33. Boothman, DA, Burrows, H, Yang, C-R, Odegaard, E, Wuerzberger, SM, Planchon, SM, Lewis, JE, Pink, J, Meyers, M, Davis TW, Van Patten, C, Sharda, N, and Kinsella, TJ. Damage sensing mechanisms in human cells after ionizing radiation. 1997; Stem Cells 15: 27-42.
34. Limoli, CL, Kaplan, MI, Corcoran, J, Meyers, M, Boothman, DA, and Morgan, WF. Chromosome instability and its relationship to other endpoints of genomic instability. 1997; Cancer Research 57(24): 5557-5563.
35. Davis TW, Van Patten, C, Meyers, M, Kinsella, TJ, Boland, R, Fishel, R, and Boothman, DA. Defective expression of the DNA mismatch repair protein, hMLH1, alters G2/M arrest following ionizing radiation. 1998; Cancer Research 58(4): 767-778.
36. Badie, B, Kramar, MH, Lau, R, Boothman, DA, Economou, J.S., and Black, K.L. Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. 1998; J. Neuro-Oncology 37: 217-222.
37. Odegaard, E, Yang, C-R, and Boothman, DA. DNA-dependent protein kinase (DNA-PK) does not play a role in adaptive survival responses to ionizing radiation. 1998; Perspectives in Environmental Health Sciences 106: 301-305.
38. Wuerzberger, SM, Planchon, SM, Pink, JJ, Bornmann, W, and Boothman, DA. ß-Lapachone-induced apoptosis in MCF-7 human breast cancer cells. 1998; Cancer Research 58: 1876-1885.
39. Limoli, CL, Hartmann, A, Shepard, L, Yang, C-R, Boothman, DA, Bartholomew, J, and Morgan, WF. Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. 1998; Cancer Research 58: 3712-3718.
40. Boothman, DA, Odegaard, E, Yang, C-R, Hosley, K, and Mendonca, M. Molecular analyses of adaptive survival responses (ASRs): role of ASRs in radiotherapy. 1998; Human and Experimental Toxicology 17: 448-453.
(Papers 41-75 were published from work at Case Western Reserve University, T.J. Kinsella, M.D., Chair)
41. Berry, SE, Garces, C, Hwang, H-S, Kunugi, K, Meyers, M, Davis, TW, Boothman, DA, and Kinsella, TJ. The mismatch repair protein, hMHL1, mediates 5-substituted halogenated thymidine analog cytotoxicity, DNA incorporation and radiosensitization in human colon cancer cells. 1999; Cancer Research 59: 1840-1845.
42. Planchon, S, Wuerzberger, S, Pink, JJ, Robertson, K, Bornmann, W, and Boothman, DA. bcl-2 protects against caspase 3-mediated apoptosis induced by ß-lapachone. 1999; Oncology Reports 6: 485-492.
43. Yang, C-R, Yeh, S-Y, Odegaard, E, Leskov, K, Hsin, H-S, Chang, C, Chen, D, Kinsella, TJ, and Boothman, DA. Isolation of Ku70 binding proteins (KUBs) 1999; Nucleic Acids Research 27: 2165-2174.
44. Badie, B, Goh, CS, Klaver, J, Herweijer, H, and Boothman, DA. Combined radiation and p53 gene therapy of malignant glioma cells. 1999; Cancer Gene Therapy 6: 155-162.
Confidential Page 39 4/8/2023
39
45. Separovic, D, Pink, JJ, Oleinick, NL, Kester, M, Boothman, DA, McLoughlin, M, Pena, LA, and Haimovitz-Friedman, A. Nieman-Pick human lymphoblasts are resistant to phthalocyanine 4-photodynamic therapy-induced apoptosis. 1999; Biomedical Biophysics Research Communication 258: 506-512.
46. Mendonca, MS, Howard, KL, Farrington, DL, Desmond, LA, Temples, TM, Mayhugh, BM, Pink, JJ, and Boothman, DA. Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. 1999; Cancer Research 59(16): 3972-3979.
47. Yang, C-R, Wilson-Van Patten, C, Planchon, SM, Wuerzberger-Davis, SM, Davis, TW, Cuthill, S, Miyamoto, S, and Boothman, DA. Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. 2000; FASEB Journal 14(2): 379-390.
48. Pink, JJ, Planchon, SM, Tagliarino, C, Wuerzberger-Davis, SM, Varnes, ME, Siegel, D, and Boothman, DA. NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of ß-lapachone cytotoxicity. 2000; J. Biological Chemistry 275(8): 5416-5422.
49. Pink, JJ, Wuerzberger-Davis, SM, Tagliarino C, Planchon, SM, Yang, X-H, Froelich, CJ, and Boothman, DA. A novel non-caspase-mediated proteolytic pathway activated in breast cancer cells during ß-lapachone-mediated apoptosis. 2000; Experimental Cell Research 255 (2): 144-155.
50. Huang, TT, Wuerzberger-Davis, SM, Seufer, BJ, Shumway, SD, Kurama, T, Boothman, DA, and Miyamoto, S. NF-kB activation by camptothecin: A linkage between nuclear DNA damage and cytoplasmic signaling events. 2000; J. Biological Chemistry 275(13): 9501-9509.
51. Yang, C-R, Odegaard, E, Leskov, K, Hosley-Eberlein, K, Criswell, T, Kinsella, TJ, and Boothman, DA. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. 2000; Proc. Natl. Acad. Sci., USA 97(11): 5907-5912.
52. Kalka, K, Ahmad, N, Criswell, T, Boothman, DA, and Mukhtar, H. Upregulation of clusterin during photodynamic therapy-mediated apoptosis of tumor cells and ablation of mouse skin tumors. 2000; Cancer Research 60(21): 5984-5987.
53. Miyamoto, S, Huang, T, Wuerzberger-Davis, S, Bornmann, WG, Pink, JJ, Tagliarino, C, Kinsella, TJ, and Boothman, DA. Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy For Improved Radiotherapy. 2000; Annals of the New York Academy of Sciences 922: 274-292.
54. Tagliarino, C, Pink, JJ, Dubyak, GR, Nieminen, A-L, and Boothman, DA. Calcium is a key signaling molecule in ß-lapachone-mediated cell death. 2001; J. Biological Chemistry 276(22): 19150-19159.
55. Planchon, SM, Pink, JJ, Tagliarino, C, Bornmann, WG, Varnes, ME, and Boothman, DA. ß-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. 2001; Experimental Cell Research 267: 95-106.
Confidential Page 40 4/8/2023
40
56. Meyers, M, Wagner, M, Hwang, H-S, Kinsella, TJ. and Boothman, DA. Role of DNA mismatch repair in FdUrd-mediated cytotoxicity. 2001; Cancer Research 61(13): 5193-5201.
57. Yan, T, Davis, TW, Schupp, JE, Hwang, H-S, Wagner, MW. Veigl, ML, Sedwick, D, Boothman, DA, and Kinsella, TJ. Mismatch repair mediated a proficient G2 arrest and cdc2 phosphorylation following high-dose rate ionizing radiation. 2001; Cancer Research 61(22): 8290-8297.
58. Tagliarino, C, Pink, JJ, and Boothman, DA. Calpains and apoptosis. 2002; Korean J. Biological Science 5: 267-274.
59. Tagliarino, C, Pink, JJ, Wuerzberg-Davis, S, and Boothman, DA. µ-Calpain activation in ß-lapachone-mediated apoptosis. 2003; Cancer Biology & Therapy 2(2): 141-152.
60. Leskov, KS, Klokov, DY, Li, J, Kinsella, TJ, and Boothman, DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. 2003; J. Biological Chemistry 278(13): 11590-11600.
61. Sun, W, Sawada, M, Hayes, P, Leskov, K, Boothman, DA, and Matsuyama, S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. 2003; Nature Cell Biology 5(4): 320-329.
62. Criswell, T, Klokov, D, Lavik, JP, Beman, M, and Boothman, DA. Transcriptional Repression of Clusterin by the p53 Tumor Suppressor Protein. 2003; Cancer Biology and Therapy 2(4): 25-31.
63. Meyers, M, Wagner, M, Hwang, A, Bruening, A, Sedwick, D, Veigl, M, and Boothman, DA. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. 2003; Oncogene 22: 7376-7388.
64. Nasongkla, N, Wiedmann, AF, Bruening, A, Beman, M, Bornmann, WG, Boothman, DA, and Gao, J. Enhancement of solubility and bioavailability of ß-lapachone using cyclodextrin inclusion complexes. 2003; J. Pharmacological Research 20(10): 1626-1633.
65. Klokov, D, Criswell, T, Sampath, L, Leskov, KS, Frinkley, K, Araki, S, Beman, M, Wilson, DL, and Boothman, DA. Clusterin: a protein with multiple functions as a potential ionizing radiation exposure marker. 2004; International Congress Series 27: 2784-93.
66. Meyers, M, Hwang, A, Wagner, M, and Boothman, DA. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. 2004; Environ. Mol. Mutagen, 44(4): 249-264.
67. Klokov, D, Criswell, T, Leskov, KS, Araki, S, Mayo, L, and Boothman, DA. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. 2004; Mutation Research, 568(1): 97-110.
68. Forouzannia, A, Schiller, J, Berlin, J, Hutson, P, Boothman, DA, Storer, B, Wilding, G, and Mehta, M. A phase I study of Topotecan, as a radiosensitizer for thoracic malignancies. 2004; Lung Cancer 44(1): 111-119.
69. Park, HJ, Ahn, K-J, Ahn, SD, Choi, E, Lee, SW, Williams, B, Kim, EJ, Griffin, R, Bey, EA, Bornmann, WG, Gao, J, Boothman, DA, and Song,
Confidential Page 41 4/8/2023
41
C-W,. Radiation increases the sensitivity of cancer cells to ß-lapachone. 2005; Int. J. Rad. Oncol., Biol., & Phys, 61(1): 212-219.
70. Nasongkla, N Shuai, X, Ai, H, Weinberg, BD, Pink, J, Boothman, DA, and Jinming G. cRGD-functionalized polymer micelles for targeted doxorubicin or ß-lapachone delivery. 2004; Angew Chem. Int. Ed. Engl., 43(46): 6323-6327.
71. Meyers, M, Mazurek, A, Schmutte, C, Fishel, R, and Boothman, DA. DNA mismatch repair detection and cellular responses to damage caused by 5-fluoro-2’-deoxyuridine exposure. 2004; J. Biological Chemistry, 280(7): 5516-5526.
72. Ough, M., Lewis, A, Bey, E, Hinkhouse, M, Ritchie, JM, Gao, J, Boothman, DA, Oberly, L., and Cullen, J, Efficacy of ß-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. 2005; Cancer Biology and Therapy, 4 (1): 54-61.
73. Criswell, T, Beman, M, Araki, S, Leskov, K, Cataldo, E, Mayo, L, and Boothman, DA. Delayed activation of IGF-1R/Src/MAPK signaling after IR regulates clusterin expression, a pro-survival protein. 2005; J. Biological Chemistry 280(14): 14212-14221.
74. Araki S, Israel S, Leskov KS, Criswell TL, Beman M., Klokov DY, Sampath L, Reinicke KE, Cataldo, E, Mayo LD, and Boothman DA. Clusterin proteins: stress-inducible polypeptides with proposed functions in multiple organ dysfunction. 2005; British Journal of Radiology 27: 106-113.
75. Reinicke, KE, Bey, EA, Bentle, MS, Pink, JJ, Ingalls, ST, Hoppel, CL, Misico, RI, Arzac, GM, Burton, G, Bornmann, WG, Sutton, D, Gao, J, Boothman, DA. Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. 2005; Clinical Cancer Research, 11(8): 3055-3064.
76. Ai, H, Pink, JJ, Shuai, X, Boothman, DA, and Gao, J. Interactions between Self-Assembled Polyelectrolyte Shells and Tumor Cells. 2005; Journal of Biomedical Materials Research, 73(3): 303-312.
77. Park, HJ, Choi, EK, Choi, J-Y, Ahn, K-J, Kim, EJ, Ji, I-M, Koo, JH, Ahn, S-D, Williams, B, Griffin, R., Boothman, DA, Chung K. Lee, CK and Song, CW. 2005; Clinical Cancer Research, 11(24): 8866-8871.
(Papers 78- were published from work at the Simmons Comprehensive Cancer Center, James KV Willson, Director)
78. Nasongkla, N, Bey, E, Ren, J, Ai, H, Khemtong, C, Guthl, JS, Chin, S-F, Sherry, AD, Boothman, DA, and Gao, J. Multifunctional polymeric micells as cancer-targeted, MRI-ultrasensitive drug delivery systems. 2006; Nanoletters 6 (11): 2427-2430.
79. Shannan, B, Seifert, M, Leskov, K, Willis, J, Boothman, DA, Tilgen, W, Reichrath, J. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation. 2006; 13(1): 12-19.
80. Wang, F, Blanco, E, Ai, H, Boothman, DA, and Gao, J. Modulating ß-lapachone release from polymer millirods through cyclodextrin
Confidential Page 42 4/8/2023
42
complexation. J. Pharmaceutical Sciences, 2006; 95(10): 2309-2319.81. Bentle, MS, Reinicke, KE, Bey, EA, Spitz, D, and Boothman, DA. Calcium
regulation of PARP-1 hyperactivation for altered cellular metabolism and inhibition of DNA repair. 2006; J Biological Chemistry, 261(44): 33684-33696.
82. Shannan, B, Seifert, M, Leskov, K, Boothman, DA, Pfohler, C, Tilgen, W, Reichrath, J. Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. 2006; Anticancer Res. 26: 2707-2716.
83. Shannan, B, Seifert, M, Boothman, DA, Tilgen, W, and Reichrath, J. Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)(2)D(3) in prostate cancer cells in vitro. 2007; J. Steroid Biochemistry and Molecular Biology 103(35): 721-725.
84. Bentle, MS, Reinicke, KE, Dong, Y, Bey, EA, and Boothman, DA. Nonhomologous end joining recombination is a resistance factor to NQO1- ß-lapachone. 2007; Cancer Res., 67: 6936-45.
85. Bey, EA, Bentle, MS, Reinicke, KE, Dong, Y, Yang, C-R, Girard, L, Minna, JD, Bornmann, WG, Gao, J, and Boothman, DA. Use of ß-lapachone for therapy against nonsmall cell lung cancer. 2007; Proc. Natl. Acad., Sci., USA 104: 11832-7.
86. Blanco, E, Bey, EA, Dong, Y, Weinberg, BD, Sutton, DM, Boothman, DA and Gao, J. Modulating ß-lapachone release from polymer millirods through cyclodextrin complexation. 2007; J. Control Release, 122: 365-374.
87. Choi, EK, Terai, K, Ji, I-M, Kook, YH, Park, KH, Oh, ET, Griffin, RJ, Lim, BU, Kim, JS, Lee, DS, Boothman, DA, Loren, M, Song, CW, and Park, HJ. Radiation-induced up-regulation of NAD(P)H:quinone oxidoreductase (NQO1) potentiates the effect of bioreductive ß-lapachone against cancer cells. 2007; Mol Cancer Ther., 9: 634-642.
88. Gomez, JA, Gama, V, Yoshida, T, Sun, W, Hayes, P, Leskov, K, Boothman, DA, Matsuyama, S. Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. 2007; Biochem. Soc., Trans. 35: 797-801.
89. Wagner, MW, Li, LS, Morales, JC, Galindo, CL, Garner, HR, Bornmann, WG, and Boothman, DA. Role of c-Abl in MMR-dependent G2 arrest responses. 2008; J. Biological Chemistry 283: 21382-21393.
90. Li, LS, Morales, JC, Hwang, A, Wagner, MW, and Boothman, DA. DNA mismatch repair-dependent activation of c-Abl/p73a/GADD45a-mediated apoptosis. 2008; J. Biological Chemistry 283: 21394-21403.
91. Dong Y, Chin S-F, Kabbani K, Xie X-J, Blanco E, Bey EA, Boothman DA, Jinming Gao. Intratumoral Implantation of ß-Lapachone-encapsulated Polymer Millirod For Prostate Cancer Therapy. 2009; Clinical Cancer Res., 15(1): 131-139.
92. Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Vassilis G. Gorgoulis VG, Papassideri IS, Zou Y, Margaritis LH, Boothman DA, Gonos, ES.
Confidential Page 43 4/8/2023
43
Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. 2009; Clinical Cancer Research, 15(1): 48-51.
93. Pucci S, Mazzarelli P, Sesti F, Boothman DA, and Spagnoli LG. Interleukin-6 affects cell death escaping mechanisms acting on bax-Ku70-clusterin interactions in human colon cancer progression. Cell Cycle 8(3): 1-9, 2009.
94. Khemtong C, Kessinger CW, Ren J, Bey EA, Boothman DA, Sherry AD, and Gao J. Turning “ON” the superparamagnetic nanoprobes for cancer molecular imaging. 2009; Cancer Research, 69(4): 1651-8.
95. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, Zhao D, Bachoo RM, Pieper RO, and Habib AA. The receptor interacting protein (RIP1) inhbits p53 induction through NF-kB activation and confers a worse prognosis in glioblastoma. 2009; Cancer Research, 69(7): 2809-2816.
96. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa HJ, Mickey B, Madden C, Elizabeth Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, and Burma S. EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. 2009; Cancer Research, 69(10): 4252-4259.
97. Park S, Zhao D, Hatanpaa KJ, Mickey BJ, Saha D, Boothman DA, Story MD, Wong ET, Burma S, Georgescu MM, Rangnekar V, Chauncey SS, and Habib AA. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and downregulation of PTEN. 2009; Cancer Res., 69(10): 4107-4115.
98. Markopoulou S, Kontargiris E, Batsi C, Tzavaras T, Trougakos I, Boothman DA, Gonos ES, and Kolettas, E. Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumulation of clusterin. 2009; FEBS J, 276(14): 3784-3799.
99. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Ahn C, Boothman DA, and Scaglioni PP. Dual PI3K/mTOR blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. 2009; Cancer Research, 69(19): 7644-7652.
b. Papers In Press to Peer-Reviewed Journals..100. Araki S, Eitel JA, Bijangi-Vishegsaraei K, Xie X-J, Danielpour D, Pollock
KE, *Boothman DA, and *Mayo LD. TGF-ß1-induced expression of Hdm2 correlates with late stage metastatic breast cancer. 2009; J. Clinical Investigation, In Press. *These authors contributed equally, both are corresponding authors.
Confidential Page 44 4/8/2023
44
c. Papers Submitted For Publication In Peer-Reviewed Scientific Journals.
101. Galindo CL, McCormick JF, McIver LJ, Skinner MA, Lewis CM, Minna JD, Boothman DA, Tomlinson GE, and Garner HR. Global germline and tumor microsatellite patterns are cancer biomarkers. 2009; Nature Medicine, Submitted.
102. Xie D, Gore C, Liu J, Pong R-C, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh, JT. The role of DAB2IP in modulating epithelial-to-mesenchymal transition (EMT) and prostate cancer metastasis. 2009; PNAS, Submitted (Dr. G. Stark, ed.).
103. Leskov, K, Araki, S, and Boothman, DA. CRM1-mediated nuclear export of nuclear clusterin (nCLU), a pro-death protein activated by ionizing radiation. J. Biological Chemistry, Submitted, 2009.
104. Blanco E, Bey EA, Khemtong C, Yang S-G, Setti-Guthi J, Kessinger C, Bornmann WG, *Boothman DA and *Gao J. ß-Lapachone micelle nanotherapeutics for non-small cell lung cancer. 2009; Cancer Research, Submitted. *These authors contributed equally, both are corresponding authors.
d. Papers In Preparation For Submission to Peer-Reviewed Journals.
105. Zou Y, Araki S, Leskov K, Criswell T, Stavnezer, E, Danielpour D, Jackson M, and Boothman DA. Regulation of the clusterin promoter by TGF-ß1 involves Smad activation. Molecular Cell, In Revision, 2009.
106. Araki, S, Boothman, DA, Jackson J, and Mayo, L. TGF-ß1 regulation of the murine double minute protein and its control of epithelial-to-mesenchymal transition. J. Clinical Investigation, In Revision, 2009.
107. Reinicke, KE, Bentle, MS, Bey EA, Dong Y, Bornmann, WG, Spitz, DR, and Boothman DA. NQO1-dependent ROS create threshold levels of DNA damage required for PARP-1 hyperactivation in -lapachone-induced cell death. 2007; Free Rad. Biol., submitted.
108. Klokov D, Sampath L, Frinkley K, Wilson D, Boothman D. Low-dose ionizing radiation-inducible clusterin promoter: Imaging and application in biodosimetry. Manuscript in preparation, 2009.
109. Mistel C, Bachoo R, Boothman DA, and Burma S. Loss of p15/Ink4b accompanies tumorigenesis triggered by particle radiation. EMBO J., In Prep., 2009.
e. Papers Published in Non-Peer-Reviewed Journals.
1. Pardee, AB and Boothman, D.A. Inhibition of carcinogenesis with DNA repair modifiers. Aspen Cancer Conference on Toxicological Pathogenesis 1988; 16: 53-102.
Confidential Page 45 4/8/2023
45
2. Boothman, DA, Briggle, TV, and Greer, S. Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacology and Therapeutics 1989; 42: 65-88.
3. Boothman, DA, and Pardee, AB. Can a DNA repair inhibitor block the tumorigenic transformation of normal cells following a genetic insult? Biol. Zent., bl., Fisher Verlag, Jeva, 1989; .108: 415-421.
4. Strudler, P, Boothman, DA, Fishel, R, Doetsch, P, Thompson, L, Sutherland, R, and Hallahan, D. Radiat. Res. 1994; 140: 143-150.
5. Meyers, M, McCaffrey, J, Odegaard, E, and Boothman, DA. X-ray-inducible transcripts and altered cell cycle regulation are involved in adaptive survival responses in human cells. 1995; Radiation Res., 141: 119-120.
6. Boothman, DA, Odegaard, E, Sahijdak, WM, Meyers, M, and Yang, C-R. Role of cyclin A in adaptive survival responses. Contributed as part of the 10th International Congress of Radiation Research, 1997.
7. Boothman, DA, Odegaard, E, Yang, C-R, Hosley, K, and Mendonca, M. Molecular analyses adaptive survival responses (ASRs): role of ASRs in radiotherapy. 1998; Belle Newsletter
8. Suzuki, M and Boothman, DA. Stress-induced premature senescence (SIPS). 2008; J. Radiat. Res. 49: 105-112.
f. Papers In Press to Non-Peer-Reviewed Journals.
g. Book Chapters and Reviews
8. Pardee, AB, Schlegel, R, and Boothman, DA. Pharmacological interference with DNA repair. In: Cerutti, P., Nygaard, OF, Simic, MG, Eds., "Anticarcinogenesis and Radiation Protection", New York: Plenum Publishing, 1987; pp. 431-436.
9. Boothman, DA, Hughes, EN, and Pardee, AB. The role of X-ray-induced DNA repair processes in mutagenesis and carcinogenesis. Mutation and the Environment, (M. Mendelsohn, Ed.), 1990; Prog. Clin. Biol. Res., 340E: 307-318.
10. Boothman, DA, Lee, S, Trask, DK, Dou, Q-P, and Hughes, EN. X-Ray-Induced proteins and Genes in human cells. UCLA Symposia On Molecular and Cellular Biology: Ionizing Radiation Damage To DNA, New Series (Wallace, S. and Painter R., Eds.) Wiley-Liss, Inc. 1990; 136: 309-317.
11. McLaughlin, WP, Schea, R, McKeever, PE, and Boothman, DA. Radiobiological effects and changes in gene expression in the central nervous system in response to ionizing radiation. In: "Molecular Genetics of Nervous System Tumors". (Levine, A.J. and Schmidek, H.H. Eds.) Wiley-Liss, Inc. 1993; Chapter 13, pp. 163-177, 1993.
12. Meyers, M, Schea, RA, Seabury, H, Petrowski, A, McLaughlin, WP, Lee, I, and Boothman, DA. Role of X-ray-induced genes and proteins in adaptive survival responses. In: "Low Dose Irradiation and Biological
13. Boothman, DA. Molecular and cellular level studies (I) of adaptive survival responses in human cells.. In: "Low Dose Irradiation and Biological Defense Mechanisms", (Sugahara T, Sagan LA, & T Aoyama, Eds.) Elsevier Science Publishers B.V. 1992; 483-484.
14. Boothman, DA. "Oncogenes and Tumor Suppressor Genes in Human Malignancies" edited by Christopher C. Benz and Edison T. Liu for Kluwer Academic Publishers. 1993.
15. Boothman, DA, Odegaard, E, Sahijdak, WM, Meyers, M, and Yang, C-R. Lack of transcription factor alterations following ultra-low doses of ionizing radiation. In: Radiation Research 1895-1995 Congress Proceedings, 10th International Congress of Radiation Research, Wurzburg, Germany, Vol. 2: 676-681, 1996.
16. Sharda, N, Yang, C-R, Kinsella, TJ, and Boothman, DA. Radiation Resistance. In: Encyclopedia of Cancer, (Bertino, J.R., ed.) Academic Press, 1996; Vol III: 1409-1419.
17. Davis, TW, Wilson-Van Patten, C, Yang, C-R, Sharda, N, Meyers, M, Kinsella, TJ, and Boothman, DA. Trasncriptional Responses to damage created by ionizing radiation. In: “DNA Damage and Repair, Vol. 2:DNA Repair in Higher Eukaryotes, (Nickoloff, J.A. and Hoekstra, M., eds.). Humana Press, Inc., Totowa, NJ. pp. 223-261, 1998.
18. Yang, C-Y, Leskov, K, Hosley-Eberlein, KJ, Criswell, TL, Mooney, MA, Pink, JJ, and Boothman, DA. Ku70-binding proteins. 2000; Radiation Research 2: 426-429.
19. Leskov, K, Criswell, TA, Antonio, S, Li, J, Yang, C-R, Kinsella, TJ, and Boothman, DA. When X-ray-inducible proteins meet DNA double strand break repair. 2001; Seminars in Radiation Oncology 11 (4): 352-372.
20. Leskov, K, Antonio, S, Criswell, T, Yang, C-R, Kinella, TJ, and Boothman, DA. Radiation-inducible clusterin (CLU): A molecular switch between life and death. 2001; Radiation Research 156 (4): 441-442.
21. Criswell, T, Leskov, K, Miyamoto, S, Luo, G, and Boothman, DA. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. 2003; Oncogene, 22: 5813-5827.
22. Klokov D, Criswell T, Sampath L, Leskov K, Frinkley K, Araki S, Beman M, Wilson D, Boothman DA. Clusterin: a protein with multiple functions as a potential ionizing radiation exposure marker. In: 1st Nagasaki Symposium of International Consortium for Medical Care of Hibakusha and radiation Life sciences. (Shibata Y, Yamashita S, Watanabe M, Tomonaga M, Eds.) Elsevier, Amsterdam, 2003.
23. Boothman, DA and Reichrath, J. New basic science initiatives for improved understanding of radiation-induced multi-organ dysfunction syndrome (MODS). 2005; British Journal of Radiology 27: 157-160.
24. Criswell, T and Boothman, DA. Regulation and functions of clusterin: A protector against stress. 2006; Acta Med. Nagasaki 50: 102-110.
Confidential Page 47 4/8/2023
47
25. Bentle, MS, Bey, EA, Dong, Y., Reinicke, KE, and Boothman, DA. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. 2006; J. Mol. Histol. 37: 5-7.
26. Suzuki, M, Cataldo, E, Veneziano, G, Shankar, B, Zou, Y, Morales, J, and Boothman, DA. Secretory clusterin (sCLU) is a hallmark sensor of DNA damage, cell stress and cellular senescence: Evidence for a similar regulation of sCLU expression after cellular stress and replicative senescence. 2006; Int. Congress Series, 49 (2): 105-112.
27.Shannan B , Seifert M, Leskov K, Boothman DA, Pfohler C, Tilgen W, Reichrath J. Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. 2006; Anticancer Res. 26 (4A): 2707-16.
28.Bey, EA, Wuerzberger-David, SM, Pink, JJ, Yang, C-R, Araki, S, Reinicke, KE, Bentle, MS, Dong, Y, Cataldo, E, Criswell, TL, Wagner, MW, Li, L, Gao, J, and Boothman, DA. Mornings with Art, lessons learned: Feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. 2006; J. Cell. Phsyiol. 209 (3): 604-610.
29.Shannan, B, Seifert, M, Boothman, DA, Tilgen, W, and Reichrath, J. Clusterin and DNA repair: A new function in cancer for a key player in apoptosis and cell cycle control. 2006; J. Mol. Histol. 37 (5-7): 183-188.
30.Trougakos IP, Djeu, YJ, Gonos ES, and Boothman DA. Advances and challenges in basic and translational research on clusterin. 2009; Cancer Research, 69(2): 403-406.
31.Zou, Y, Goetz, EM, Suzuki M, and Boothman DA. Secretory clusterin in a marker of tumor progression regulated by IGF-1 and Wnt signaling pathways. In “Radiation Health Risk Sciences” (Eds: M. Nakashima, M. Takamura, L. Tsukasaki, Y. Nagayama, and S. Yamashita), Springer, pp. 204-211.
32. Chauncey SS, Boothman DA, and Habib AA. The receptor interacting protein 1 mediates a link between NFkappaB and PI3-kinase signaling. 2009; Cell Cycle 8 (17): 2671-2672.
Book Chapters and Reviews In Press.
1. Li, L, Morales, JC, Veigl M, Sedwick D, Greer S, Meyers M, Wagner M, Fishel R, and Boothman DA. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new ‘drugable’ targets. 2009; British J. Pharmacology, In Press, (Sept. 23).
